```
=> d his

     (FILE 'HOME' ENTERED AT 10:26:30 ON 26 JAN 2010)

     FILE 'REGISTRY' ENTERED AT 10:26:39 ON 26 JAN 2010
L1              STRUCTURE UPLOADED
L2           50 S L1
L3         8052 S L1 SSS FUL
L4              STRUCTURE UPLOADED
L5         7510 S L4  SUB=L3 FUL
L6          542 S L3 NOT L5
L7      1070797 S 591.79/RID
L8          474 S L6 NOT L7
L9          462 S L8 AND CAPLUS/LC
L10          12 S L8 NOT L9

     FILE 'CAPLUS' ENTERED AT 10:33:00 ON 26 JAN 2010
L11          15 S L8
L12          12 S L11 NOT (2010/SO OR 2009/SO OR 2008/SO OR 2007/SO OR 2006/SO)

=> d ibib abs hitstr total
```

L12 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1177433 CAPLUS
DOCUMENT NUMBER: 147:469493
TITLE: Preparation of diaza-bridged heterocycle derivatives as alkaloid mimetics and solid-phase preparation method thereof
INVENTOR(S): Park, Seung Bum; Lee, Sung-Chan
PATENT ASSIGNEE(S): Seoul National University Industry Foundation, S. Korea
SOURCE: PCT Int. Appl., 72pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007117053	A1	20071018	WO 2006-KR1714	20060508
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
KR 712667	B1	20070502	KR 2006-32908	20060411
PRIORITY APPLN. INFO.:			KR 2006-32908 A	20060411

OTHER SOURCE(S): CASREACT 147:469493; MARPAT 147:469493
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R = H, each (un)substituted C1-8 linear or branched alkyl, C2-8 alkenyl, or C2-8 alkynyl; R2 = H, -(X)-R3; X = NH, NH(CO), CO, (CO), SO, SO or (CH2)n (wherein n = an integer of 1-4); R3 = C1-8 linear or branched alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, C6-20 aryl, C5-20 heterocyclyl, halo-C6-20 haloaryl, etc.; Ar = (un)substituted C6-20 aryl; provided that in the case where Ar is Ph, it contains at least one substituent] are prepared by the solid-phase preparation method which comprises using a solid-phase bromoacetal resin (II; R4 = Br) as a starting material to react with amino acids and various derivs. thereof, and then subjecting the product to solid-phase cleavage in a one-pot reaction by means of the Pictet-Spengler mechanism under acidic conditions to obtain the objective compds. These compds. have the structure which can be commonly shown in alkaloids which are frequently found in natural products, and the substances having biol. activity and are natural product mimetics which are expected to have anticancer effect, antivirus effect, antiinflammatory effect, or pharmacol. activity in heart circulating

system disease, immune system disease, or central nervous system disease. By this process a library of various compds. can be prepared at the same time, and this preparation method allows more rapid and massive production of a variety of lead compds. for drug discovery. In general procedure, the bromoacetal resin II (R5 = Br) was reacted with 12 primarylamines, i.e. isobutylamine, 3-trifluoromethylbenzylamine, 3-phenylpropylamine, 2-aminomethyltetrahydrofuran, 3-methylbutylamine, 4-fluorobenzylamine, 2-(4-methoxyphenyl)ethylamine, 3-methoxypropylamine, 4-methoxybenzylamine, benzylamine, butylamine, and (2,2-diphenylethyl)amine, to give aminoacetal resin II (R4 = NHR1; R1 = iso-Bu, 3-trifluoromethylbenzyl, 3-phenylpropyl, (tetrahydrofuran-2-yl)methyl, 3-methylbutyl, 4-fluorobenzyl, 2-(4-methoxyphenyl)ethyl, 3-methoxypropyl, 4-methoxybenzyl, benzyl, Bu, benzhydryl) which was condensed with Fmoc-Trp(Boc)-OH or N-Fmoc-O,O-bis(tert-butyldimethylsilyl)-L-DOPA using HATU and diisopropylethylamine in DMF to give amino acid amide-linked acetal resin (III and IV; R5 = Fmoc; R1 = same as above). III or IV (R5 = Fmoc; R1 = same as above) was treated with 25% piperidine to remove the Fmoc group, followed by condensation with 8-carboxylic acids, i.e. acetic acid, 2-(naphthalen-2-yl)acetic acid, 2-phenylacetic acid, 3-phenyl-2-propenoic acid, 3-phenylpropanoic acid, 2-(2,6-dichlorophenyl)acetic acid, 2-bromobenzoic acid, and furan-2-carboxylic acid, or 8 isocyanates, i.e. benzyl isocyanate, allyl isocyanate, phenethyl isocyanate, hexyl isocyanate, iso-Pr isocyanate, 4-methoxyphenyl isocyanate, 4-chlorophenyl isocyanate, and 3,5-dimethylphenyl isocyanate, to give III or IV [R1 = same as above; R5 = COR3 or CONHR3'; COR3 = acetyl, 2-(naphthalen-2-yl)acetyl, 2-phenylacetyl, 3-phenyl-2-propenoyl, 3-phenylpropanoyl, 2-(2,6-dichlorophenyl)acetyl, 2-bromobenzoyl, furan-2-ylcarbonyl; R3' = benzyl, allyl, phenethyl, hexyl, iso-Pr, 4-methoxyphenyl, 4-chlorophenyl, 3,5-dimethylphenyl] which underwent the Pictet-Spengler cyclization in neat formic acid at room temperature and resin cleavage reaction with neat formic acid at 60° to give 1,2,3,4,5,6-hexahydro-1,5-iminoazocino[4,5-b]indol-4-one derivs. (V; R6 = COR3 or CONHR3'; COR3, R3' = same as above) and 4,5-dihydroxy-11,13-diazatricyclo[7.3.1.02'7]trideca-2(7),3,5-trien-10-one derivs. (VI; R6 = COR3 or CONHR3'; COR3, R3' = same as above) as the final products.

IT 952667-08-2P, (1S,5S)-12-(3-Phenyl-2-propenoyl)-3-[3-(trifluoromethyl)benzyl]-1,2,3,4,5,6-hexahydro-1,5-iminoazocino[4,5-b]indol-4-one 952667-10-6P, (1S,5S)-12-(3-Phenyl-2-propenoyl)-3-(4-fluorobenzyl)-1,2,3,4,5,6-hexahydro-1,5-iminoazocino[4,5-b]indol-4-one 952667-15-1P, (1S,5S)-12-(3-Phenyl-2-propenoyl)-3-(4-methoxybenzyl)-1,2,3,4,5,6-hexahydro-1,5-iminoazocino[4,5-b]indol-4-one 952667-16-2P, (1S,5S)-12-(3-Phenyl-2-propenoyl)-3-(benzyl)-1,2,3,4,5,6-hexahydro-1,5-iminoazocino[4,5-b]indol-4-one 952668-95-0P, (1R,9S)-13-(3-Phenyl-2-propenoyl)-11-[3-(trifluoromethyl)benzyl]-4,5-dihydroxy-11,13-diazatricyclo[7.3.1.02'7]trideca-2(7),3,5-trien-10-one 952668-97-2P, (1R,9S)-13-(3-Phenyl-2-propenoyl)-11-(4-fluorobenzyl)-4,5-dihydroxy-11,13-diazatricyclo[7.3.1.02'7]trideca-2(7),3,5-trien-10-one 952669-02-2P, (1R,9S)-13-(3-Phenyl-2-propenoyl)-11-(4-methoxybenzyl)-4,5-dihydroxy-11,13-diazatricyclo[7.3.1.02'7]trideca-2(7),3,5-trien-10-one 952669-03-3P, (1R,9S)-13-(3-Phenyl-2-propenoyl)-11-(benzyl)-4,5-dihydroxy-11,13-diazatricyclo[7.3.1.02'7]trideca-2(7),3,5-trien-10-one
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(preparation of library of diaza-bridged heterocycle derivs. as alkaloid mimetics and solid-phase preparation method thereof)

RN 952667-08-2 CAPLUS
CN 1,5-Imino-4H-azocino[4,5-b]indol-4-one, 1,2,3,5,6,11-hexahydro-12-(1-oxo-3-phenyl-2-propen-1-yl)-3-[[3-(trifluoromethyl)phenyl]methyl]-, (1S,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 952667-10-6 CAPLUS
CN 1,5-Imino-4H-azocino[4,5-b]indol-4-one, 3-[(4-fluorophenyl)methyl]-1,2,3,5,6,11-hexahydro-12-(1-oxo-3-phenyl-2-propen-1-yl)-, (1S,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 952667-15-1 CAPLUS
CN 1,5-Imino-4H-azocino[4,5-b]indol-4-one, 1,2,3,5,6,11-hexahydro-3-[(4-methoxyphenyl)methyl]-12-(1-oxo-3-phenyl-2-propen-1-yl)-, (1S,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 952667-16-2 CAPLUS
CN 1,5-Imino-4H-azocino[4,5-b]indol-4-one, 1,2,3,5,6,11-hexahydro-12-(1-oxo-3-phenyl-2-propen-1-yl)-3-(phenylmethyl)-, (1S,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 952668-95-0 CAPLUS
CN 1,5-Imino-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-8,9-dihydroxy-11-(1-oxo-3-phenyl-2-propen-1-yl)-3-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 952668-97-2 CAPLUS
CN 1,5-Imino-3-benzazocin-4(1H)-one, 3-[(4-fluorophenyl)methyl]-2,3,5,6-tetrahydro-8,9-dihydroxy-11-(1-oxo-3-phenyl-2-propen-1-yl)-, (1R,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 952669-02-2 CAPLUS
CN 1,5-Imino-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-8,9-dihydroxy-3-[(4-methoxyphenyl)methyl]-11-(1-oxo-3-phenyl-2-propen-1-yl)-, (1R,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 952669-03-3 CAPLUS

CN 1,5-Imino-3-benzazocin-4(1H)-one, 2,3,5,6-tetrahydro-8,9-dihydroxy-11-(1-oxo-3-phenyl-2-propen-1-yl)-3-(phenylmethyl)-, (1R,5S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1170489 CAPLUS
DOCUMENT NUMBER: 143:440438
TITLE: Preparation of bicyclic heterocycles as CCR-1 and MIP1α antagonists useful against inflammatory diseases and as radiolabeled markers for neuroimaging
INVENTOR(S): Heng, Richard; Revesz, Laszlo; Schlapbach, Achim; Waelchli, Rudolf
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 205 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005103054	A2	20051103	WO 2005-EP4422	20050425
WO 2005103054	A3	20070208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005235724	A1	20051103	AU 2005-235724	20050425
AU 2005235724	B2	20081030		
CA 2559917	A1	20051103	CA 2005-2559917	20050425
EP 1794164	A2	20070613	EP 2005-737794	20050425
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
BR 2005010313	A	20071016	BR 2005-10313	20050425
JP 2007534678	T	20071129	JP 2007-508868	20050425
US 20070196270	A1	20070823	US 2006-599819	20061011
KR 2007014154	A	20070131	KR 2006-722181	20061025
KR 845356	B1	20080709		
MX 2006012380	A	20070117	MX 2006-12380	20061026
IN 2006CN03917	A	20070615	IN 2006-CN3917	20061026
CN 101238131	A	20080806	CN 2005-80013239	20061026
KR 2008015151	A	20080218	KR 2008-702184	20080128

PRIORITY APPLN. INFO.: GB 2004-9236 A 20040426
WO 2005-EP4422 W 20050425
KR 2006-722181 A3 20061025
OTHER SOURCE(S): CASREACT 143:440438; MARPAT 143:440438
GI



I



II

AB Bicyclic heterocycles (shown as I; variables defined below; e.g. (E)-N-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]ethanamide (shown as II)) or a pharmaceutically acceptable salt or ester thereof, were prepared and found to be antagonists of CCR-1 and MIP1α and claimed useful for treatment of diseases and conditions in which CCR-11 is implicated, e.g. inflammatory diseases. Compds. I are also claimed useful as radiolabeled markers for neuroimaging, e.g. for diagnosis of Alzheimer's disease. Methods of preparation are claimed and .apprx.160 example prepns. are included. For example, II was prepared in 6 steps (94, 87, 46, 68, 100 and 56 % yields) starting from (E)-3-(2-amino-4-chlorophenyl)-2-propenoic acid Me ester and involving intermediates (E)-3-[2-[(tert-butoxycarbonyl)amino]-4-chlorophenyl]-2-propenoic acid Me ester, (E)-3-[2-[(tert-butoxycarbonyl)amino]-4-chlorophenyl]-2-propenoic acid, 3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]octane/8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]octane, (E)-[5-chloro-2-[3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]carbamic acid tert-Bu ester, and (E)-3-(2-amino-4-chlorophenyl)-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]prop-2-enone. For I: R1, R2 and R3 = H, cyano, halo, nitro or (un)substituted oxy, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, carbonyl, amino, S, cycloalkyl, heterocycloalkyl, aryl, heteroaryl or a substituent forming a bicyclic ring system of which the Ph ring to which it is attached forms part of the bicycle for example butadiene forming naphthyl, or heterobutadiene forming quinolinyl, quinoxalinyl or isoquinolinyl. R4 = H, cyano, halo, nitro or (un)substituted oxy, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, carbonyl, amino, S, cycloalkyl, heterocycloalkyl, aryl, heteroaryl or a substituent forming a bicyclic ring system of which the Ph ring to which it is attached forms part of the bicycle for example butadiene forming naphthyl, or heterobutadiene forming quinolinyl, quinoxalinyl or isoquinolinyl. X is -CH:CHCO-; Y is -(CH2)n- where n = 1-6, -CH2OCH2- or -CH2NRCH2- and is bonded to two of the ring C atoms, bonding being to either the ring C atoms a and b or the ring C atoms c and d; wherein R = H, (un)substituted: C1-7 alkyl, carbonyl, acyl, acetyl or sulfonyl; Z is N or CH-; Q is -CH2-, -NH- or -O-; addnl. details including provisos are given in the claims.

IT 868406-37-5P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]methanesulfonamide 868407-39-0P, 9-[2-(2-Acetylamino-4-chlorophenoxy)acetyl]-7-(4-

fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-45-8P, 7-[2-(2-Acetylamino-4-chlorophenoxy)acetyl]-9-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-48-1P, (E)-N-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]ethanamide 868407-69-6P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]acetamide RL: DGN (Diagnostic use); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate, neuroimaging marker; preparation of bicyclic heterocycles as CCR-1 antagonists)

RN 868406-37-5 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-39-0 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[2-[2-(acetylamino)-4-chlorophenoxy]acetyl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 868407-45-8 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 7-[2-[2-(acetylamino)-4-chlorophenoxy]acetyl]-9-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 868407-48-1 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-69-6 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 868406-29-5P, (E)-N-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]ethanamide
868406-33-1P, (E)-N-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]-N'-cyanoguanidine
868406-34-2P, (E)-N-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]-2-dimethylaminoethanamide 868406-36-4P, (E)-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]urea 868406-38-6P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-

3-oxopropenyl]phenyl]-2-methoxyacetamide 868406-39-7P,
1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-
3-oxopropenyl]phenyl]-3-methylurea 868406-40-0P,
3-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-
3-oxopropenyl]phenyl]-1,1-dimethylurea 868406-41-1P,
1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-
3-oxopropenyl]phenyl]-3-ethylurea 868406-42-2P,
1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-
3-oxopropenyl]phenyl]-3-propylurea 868406-43-3P,
1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-
3-oxopropenyl]phenyl]-3-isopropylurea 868406-44-4P,
1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-
3-oxopropenyl]phenyl]-3-cyclopropylurea 868406-45-5P,
1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-
3-oxopropenyl]phenyl]-3-(tetrahydropyran-4-yl)urea 868406-46-6P
, 3-Oxopiperazine-1-carboxylic acid
N-[5-chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-
3-oxopropenyl]phenyl]amide 868406-47-7P,
2-Oxooxazolidine-3-sulfonic acid N-[5-chloro-2-[(E)-3-[3-(4-fluorobenzyl)-
3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]amide
868406-48-8P, N-[5-Chloro-2-[(E)-3-[8-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl]phenyl]methanesulfonamide
868406-50-2P, 1-[5-Chloro-2-[(E)-3-[8-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl]phenyl]-3-ethylurea
868406-51-3P, N-[5-Chloro-2-[(E)-3-[8-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl]phenyl]-2-methoxyacetamide
868406-52-4P, [5-Chloro-2-[(E)-3-[8-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl]phenyl]urea
868406-53-5P, (E)-N-[5-Chloro-2-[3-[8-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl]phenyl]ethanamide
868406-54-6P, 3-[5-Chloro-2-[(E)-3-[8-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl]phenyl]-1,1-dimethylurea
868406-55-7P, 1-[5-Chloro-2-[(E)-3-[8-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl]phenyl]-3-methylurea
868406-56-8P, 1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methoxyphenyl]-3-methylurea
868406-59-1P, [5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methoxyphenyl]urea
868406-60-4P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methoxyphenyl]acetamide
868406-61-5P, 1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methoxyphenyl]-3-
cyclopropylurea 868406-62-6P,
N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-
3-oxopropenyl]-4-methoxyphenyl]methanesulfonamide 868406-63-7P
, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-
yl]-3-oxopropenyl]-4-methoxyphenyl]-2-dimethylaminoacetamide
868406-64-8P, 3-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methoxyphenyl]-1,1-
dimethylurea 868406-65-9P,
5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-
oxopropenyl]-4-methoxy-N,N-dimethylbenzenesulfonamide
868406-70-6P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-(1-hydroxy-1-
methylethyl)phenyl]acetamide 868406-75-1P,
N-[5-Chloro-4-ethoxy-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-
diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]acetamide

868406-78-4P, N-[5-Chloro-4-ethoxy-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]methanesulfonamide 868406-79-5P, 1-[5-Chloro-4-ethoxy-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]urea 868406-80-8P, [5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]urea 868406-85-3P, 1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]-3-methylurea 868406-86-4P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]acetamide 868406-87-5P , 3-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]-1,1-dimethylurea 868406-88-6P, 3-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]-1,1-dimethylsulfamide 868406-89-7P, 5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-N,N-dimethyl-4-trifluoromethoxybenzenesulfonamide 868406-93-3P, [5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methylphenyl]urea 868406-97-7P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methylphenyl]methanesulfonamide 868406-98-8P, 3-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methylphenyl]-1,1-dimethylsulfamide 868406-99-9P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methylphenyl]-2-methoxyacetamide 868407-00-5P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methylphenyl]acetamide 868407-01-6P, 1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methylphenyl]-3-methylurea 868407-02-7P, 3-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methylphenyl]-1,1-dimethylurea 868407-03-8P, 3-Oxopiperazine-1-carboxylic acid N-[5-chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methylphenyl]amide 868407-04-9P, 1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methylphenyl]-3-cyclopropylurea 868407-05-0P, 1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methylphenyl]-3-tert-butylsulfamide 868407-06-1P, 5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methyl-N,N-dimethylbenzenesulfonamide 868407-07-2P, N-[3'-Amino-2-chloro-5-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]biphenyl-4-yl]acetamide 868407-13-0P, N-[3'-Acetylamino-2-chloro-5-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]biphenyl-4-yl]acetamide 868407-14-1P, N-[2-Chloro-5-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-3'-ureidobiphenyl-4-yl]acetamide 868407-15-2P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-(pyrazin-2-yl)phenyl]acetamide 868407-21-0P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-(pyridin-3-yl)phenyl]acetamide 868407-22-1P, [5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-(pyridin-3-yl)phenyl]urea 868407-25-4P,

N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-(pyridin-2-yl)phenyl]acetamide 868407-26-5P, N-[3-Chloro-6-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-2,4-dimethoxyphenyl]acetamide 868407-31-2P, (E)-N-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]ethanamide 868407-34-5P, (E)-1-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]urea 868407-36-7P, (E)-N-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]-N'-cyanoguanidine 868407-37-8P, (E)-N-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]-2-dimethylaminoethanamide 868407-44-7P, N-[5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]phenyl]acetamide 868407-47-0P, N-[5-Chloro-2-[2-[9-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-3-yl]-2-oxoethoxy]phenyl]acetamide 868407-54-9P, (E)-N-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]-2-dimethylaminoethanamide 868407-56-1P , (E)-N-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]methanesulfonamide 868407-58-3P, [5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]urea monohydrochloride 868407-60-7P, (E)-N-[5-Chloro-4-fluoro-2-[3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]ethanamide 868407-63-0P, [5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]urea 868407-67-4P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]methanesulfonamide 868407-68-5P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]acetamide 868407-72-1P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]methanesulfonamide monohydrochloride 868407-74-3P , [5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]urea monohydrochloride 868407-76-5P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]-2-dimethylaminoacetamide dihydrochloride 868407-78-7P, N-[2-[(E)-3-[3-Acetyl-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-5-chloro-4-methoxyphenyl]acetamide 868407-80-1P, 9-[(E)-3-(2-Acetylamino-4-chloro-5-methoxyphenyl)-2-propenoyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid methylamide 868407-81-2P, 9-[(E)-3-(2-Acetylamino-4-chloro-5-methoxyphenyl)-2-propenoyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid dimethylamide 868407-82-3P, 9-[(E)-3-(2-Acetylamino-4-chloro-5-methoxyphenyl)-2-propenoyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid methyl ester 868407-83-4P, N-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-7-methylsulfonyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]acetamide 868407-84-5P, 5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methylsulfonyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-N,N-dimethyl-4-trifluoromethoxybenzenesulfonamide 868407-85-6P, N-[2-[(E)-3-[3-Acetyl-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-5-chloro-4-fluorophenyl]acetamide

868407-86-7P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methylphenyl]acetamide monohydrochloride 868407-89-0P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methylphenyl]methanesulfonamide hydrochloride 868407-90-3P, [5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methylphenyl]urea hydrochloride 868407-91-4P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methylphenyl]-2-dimethylaminoacetamide dihydrochloride 868407-92-5P, [5-Chloro-2-[(E)-3-[9-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-3-yl]-3-oxopropenyl]-4-methylphenyl]urea 868407-94-7P, N-[5-Chloro-2-[(E)-3-[9-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-3-yl]-3-oxopropenyl]-4-methylphenyl]methanesulfonamide 868407-95-8P, N-[5-Chloro-2-[(E)-3-[9-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-3-yl]-3-oxopropenyl]-4-methylphenyl]acetamide 868407-96-9P, N-[2-[(E)-3-[3-Acetyl-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-5-chloro-4-methylphenyl]acetamide 868407-97-0P, [5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methylphenyl]urea hydrochloride 868407-98-1P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methylphenyl]methanesulfonamide hydrochloride 868407-99-2P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methylphenyl]acetamide hydrochloride 868408-00-8P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]acetamide 868408-01-9P, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]methanesulfonamide 868408-02-0P, [5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]urea 868408-03-1P, 1-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]-3,3-dimethylsulfamide 868408-04-2P, N-[5-Chloro-2-[2-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]phenyl]acetamide 868408-07-5P, N-[5-Chloro-2-[2-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-2-oxoethoxy]phenyl]acetamide 868408-11-1P, (E)-N-[5-Chloro-2-[3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]phenyl]ethanamide 868408-14-4P, (E)-N-[5-Chloro-2-[3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]ethanamide 868408-17-7P, (E)-1-[5-Chloro-2-[3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]urea 868408-18-8P, (E)-N-[5-Chloro-2-[3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]-N'-cyanoguanidine 868408-19-9P, (E)-[5-Chloro-2-[3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]phenyl]urea 868408-20-2P, N-[5-Chloro-2-[(E)-3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-4-methoxyphenyl]acetamide 868408-21-3P, N-[5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-

9-yl]-3-oxopropenyl]-4-methoxyphenyl]acetamide 868408-22-4P, N-[5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]methanesulfonamide 868408-23-5P, [5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]urea 868408-24-6P, 1-[5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]-3-methylurea 868408-25-7P, 1-[5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]-3-cyclopropylurea 868408-26-8P, 5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxy-N,N-dimethylbenzenesulfonamide 868408-27-9P, N-[3-Chloro-6-[(E)-3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-2,4-dimethoxyphenyl]acetamide 868408-28-0P, N-[3-Chloro-6-[(E)-3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-2-methoxyphenyl]acetamide 868408-29-1P, N-[5-Chloro-2-[(E)-3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-4-methoxyphenyl]methanesulfonamide 868408-30-4P, [5-Chloro-2-[(E)-3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-4-methoxyphenyl]urea 868408-32-6P, Cyclopropanecarboxylic acid N-[5-chloro-2-[(E)-3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-4-methoxyphenyl]amide 868408-34-8P, N-[5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]acetamide 868408-36-0P, [5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]urea 868408-37-1P, 1-[5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]-3-methylurea 868408-38-2P, N-[5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]isobutyramide 868408-39-3P, 5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-N,N-dimethyl-4-trifluoromethoxybenzenesulfonamide 868408-40-6P, 1-[5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]-3,3-dimethylsulfamide 868408-41-7P, 1-[5-Chloro-4-(cyclopropylmethoxy)-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]-3-methylurea 868408-49-5P, N-[5-Chloro-4-(cyclopropylmethoxy)-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]acetamide 868408-50-8P, N-[5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methylphenyl]acetamide 868408-51-9P, N-[5-Chloro-2-[(E)-3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-4-methylphenyl]acetamide 868408-52-0P, N-[5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-(pyrazin-2-yl)phenyl]acetamide 868408-53-1P, N-[5-Chloro-2-[(E)-3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-4-(pyrazin-2-yl)phenyl]acetamide 868408-54-2P, N-[5-Chloro-2-[(E)-3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-4-(pyridin-2-yl)phenyl]acetamide 868408-55-3P, N-[5-Chloro-2-[(E)-3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-(pyridin-2-yl)phenyl]acetamide 868408-56-4P,

N-[5-Chloro-2-[(E)-3-[(1S,3R,5R)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-(pyrazin-2-yl)phenyl]acetamide 868408-57-5P
, N-[5-Chloro-2-[(E)-3-[(1S,3R,5R)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-(pyridin-2-yl)phenyl]acetamide 868408-58-6P, [5-Chloro-2-[(E)-3-[(1R,3R,5S)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methoxyphenyl]urea 868408-60-0P, N-[5-Chloro-2-[(E)-3-[(1R,3R,5S)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methoxyphenyl]acetamide 868408-61-1P, [5-Chloro-2-[(E)-3-[(1R,3R,5S)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]urea 868408-62-2P, N-[5-Chloro-2-[(E)-3-[(1R,3R,5S)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]acetamide 868408-63-3P, 5-Chloro-2-[(E)-3-[(1R,3R,5S)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methoxy-N,N-dimethylbenzenesulfonamide 868408-64-4P, N-[5-Chloro-2-[(E)-3-[(1S,5R,8S)-8-[(4-fluorophenyl)amino]-3-azabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl]-4-methoxyphenyl]acetamide 868408-67-7P, [5-Chloro-2-[(E)-3-[(1S,5R,9S)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]urea 868408-71-3P, N-[5-Chloro-2-[(E)-3-[(1S,5R,9S)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]acetamide 868408-72-4P, N-[5-Chloro-2-[(E)-3-[(1S,5R,9R)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-4-methoxyphenyl]acetamide 868408-73-5P, N-[5-Chloro-2-[(E)-3-[(1S,5R,7S)-7-[(4-fluorophenyl)amino]-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]acetamide 868408-76-8P, N-[5-Chloro-2-[(E)-3-[(1S,5R,7S)-7-[(4-fluorophenyl)amino]-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]acetamide 868408-77-9P, 3-[5-Chloro-2-[(E)-3-[(1S,5R,7S)-7-[(4-fluorophenyl)amino]-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]-1,1-dimethylurea 868408-79-1P, 5-Chloro-2-[(E)-3-[(1S,5R,7S)-7-[(4-fluorophenyl)amino]-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-(trifluoromethoxy)-N,N-dimethylbenzenesulfonamide 868408-80-4P, N-[5-Chloro-4-fluoro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]acetamide 868408-81-5P, N-[5-Chloro-4-fluoro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]acetamide 868408-83-7P, 6-[5-Chloro-4-fluoro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]-4,6-diazaspiro[2.4]heptane-5,7-dione 868408-86-0P, 6-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methoxyphenyl]-4,6-diazaspiro[2.4]heptane-5,7-dione 868408-90-6P, 6-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]-4,6-diazaspiro[2.4]heptane-5,7-dione 868408-94-0P, 3-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-trifluoromethylphenyl]-5-methylimidazolidine-2,4-dione 868408-98-4P, 3-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]-5-

methylimidazolidine-2,4-dione 868409-01-2P, 3-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]-4-methoxyphenyl]-5-methylimidazolidine-2,4-dione 868547-42-6P, N-[5-Chloro-2-[(E)-3-[(1S,5R,9R)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-4-trifluoromethoxyphenyl]acetamide 868547-44-8P, N-[5-Chloro-2-[(E)-3-[(1S,5R,9S)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]-4-methoxyphenyl]acetamide
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate, neuroimaging marker; preparation of bicyclic heterocycles as CCR-1 antagonists)

RN 868406-29-5 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-33-1 CAPLUS
CN Guanidine, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-N'-cyano- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-34-2 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-36-4 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-38-6 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-2-methoxy- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-39-7 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-N'-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-40-0 CAPLUS
CN Urea, N'-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-41-1 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-N'-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-42-2 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-N'-propyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-43-3 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-N'-(1-methylethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-44-4 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-N'-cyclopropyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-45-5 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-N'-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-46-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-3-oxo- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-47-7 CAPLUS
CN 3-Oxazolidinesulfonamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-48-8 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[8-[(4-fluorophenyl)methyl]-3,8-

diazabicyclo[3.2.1]oct-3-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-50-2 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxo-1-propen-1-yl]phenyl]-N'-ethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-51-3 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxo-1-propen-1-yl]phenyl]-2-methoxy- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-52-4 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-53-5 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-54-6 CAPLUS
CN Urea, N'-[5-chloro-2-[(1E)-3-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxo-1-propen-1-yl]phenyl]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-55-7 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxo-1-propen-1-yl]phenyl]-N'-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-56-8 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-N'-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-59-1 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-60-4 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-61-5 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-N'-cyclopropyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-62-6 CAPLUS

CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-63-7 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-2-(dimethylamino)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-64-8 CAPLUS
CN Urea, N'-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-65-9 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxy-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-70-6 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(1-hydroxy-1-methylethyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-75-1 CAPLUS
CN Acetamide, N-[5-chloro-4-ethoxy-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-

diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-78-4 CAPLUS
CN Methanesulfonamide, N-[5-chloro-4-ethoxy-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-79-5 CAPLUS
CN Urea, N-[5-chloro-4-ethoxy-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-80-8 CAPLUS

CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-85-3 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]-N'-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-86-4 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-87-5 CAPLUS
CN Urea, N'-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-88-6 CAPLUS
CN Sulfamide, N'-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-89-7 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-N,N-dimethyl-4-(trifluoromethoxy)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-93-3 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-97-7 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-98-8 CAPLUS
CN Sulfamide, N'-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-99-9 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-2-methoxy- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-00-5 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-01-6 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-N'-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-02-7 CAPLUS
CN Urea, N'-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-03-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-3-oxo- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-04-9 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-N'-cyclopropyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-05-0 CAPLUS
CN Sulfamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-N'-(1,1-dimethylethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-06-1 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-N,N,4-trimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-07-2 CAPLUS
CN Acetamide, N-[3'-amino-2-chloro-5-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-13-0 CAPLUS
CN Acetamide, N-[3'-(acetylamino)-2-chloro-5-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-14-1 CAPLUS
CN Acetamide, N-[3'-[(aminocarbonyl)amino]-2-chloro-5-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-15-2 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(2-pyrazinyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-21-0 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(3-pyridinyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-22-1 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(3-pyridinyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-25-4 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(2-pyridinyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-26-5 CAPLUS
CN Acetamide, N-[3-chloro-6-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-2,4-dimethoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-31-2 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-34-5 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-36-7 CAPLUS
CN Guanidine, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]-N'-cyano- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-37-8 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-44-7 CAPLUS
CN Acetamide, N-[5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 868407-47-0 CAPLUS
CN Acetamide, N-[5-chloro-2-[2-[9-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-3-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 868407-54-9 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-56-1 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-58-3 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 868407-60-7 CAPLUS
CN Acetamide, N-[5-chloro-4-fluoro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-63-0 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-67-4 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-68-5 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-72-1 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 868407-74-3 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 868407-76-5 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-2-(dimethylamino)-, hydrochloride (1:2) (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-78-7 CAPLUS
CN Acetamide, N-[2-[(1E)-3-[3-acetyl-7-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-5-chloro-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-80-1 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxamide, 9-[(2E)-3-[2-(acetylamino)-4-chloro-5-methoxyphenyl]-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-N-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-81-2 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxamide,
9-[(2E)-3-[2-(acetylamino)-4-chloro-5-methoxyphenyl]-1-oxo-2-propen-1-yl]-
7-[(4-fluorophenyl)methyl]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-82-3 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid,
9-[(2E)-3-[2-(acetylamino)-4-chloro-5-methoxyphenyl]-1-oxo-2-propen-1-yl]-
7-[(4-fluorophenyl)methyl]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-83-4 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-(methylsulfonyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-84-5 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-(methylsulfonyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-N,N-dimethyl-4-(trifluoromethoxy)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-85-6 CAPLUS
CN Acetamide, N-[2-[(1E)-3-[3-acetyl-7-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-5-chloro-4-fluorophenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-86-7 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 868407-89-0 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 868407-90-3 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 868407-91-4 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-2-(dimethylamino)-, hydrochloride (1:2) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 868407-92-5 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-3-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-94-7 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-3-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-95-8 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-3-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-96-9 CAPLUS
CN Acetamide, N-[2-[(1E)-3-[3-acetyl-7-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-5-chloro-4-methylphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-97-0 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-, hydrochloride (1:?) (CA INDEX NAME)

Double bond geometry as shown.



● x HCl

RN 868407-98-1 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-, hydrochloride (1:?) (CA INDEX NAME)

Double bond geometry as shown.



● x HCl

RN 868407-99-2 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]-, hydrochloride (1:?) (CA INDEX NAME)

Double bond geometry as shown.



● x HCl

RN 868408-00-8 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-01-9 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-02-0 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-03-1 CAPLUS
CN Sulfamide, N'-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-04-2 CAPLUS
CN Acetamide, N-[5-chloro-2-[2-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 868408-07-5 CAPLUS
CN Acetamide, N-[5-chloro-2-[2-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 868408-11-1 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-14-4 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-17-7 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-18-8 CAPLUS
CN Guanidine, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]-N'-cyano- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-19-9 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-20-2 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-21-3 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-22-4 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-23-5 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-24-6 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-N'-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-25-7 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-N'-cyclopropyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-26-8 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxy-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-27-9 CAPLUS
CN Acetamide, N-[3-chloro-6-[(1E)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-2,4-dimethoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-28-0 CAPLUS
CN Acetamide, N-[3-chloro-6-[(1E)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-2-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-29-1 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-30-4 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-

diazabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-32-6 CAPLUS
CN Cyclopropanecarboxamide, N-[5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-34-8 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-36-0 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-37-1 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]-N'-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-38-2 CAPLUS
CN Propanamide, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-39-3 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-N,N-dimethyl-4-(trifluoromethoxy)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-40-6 CAPLUS
CN Sulfamide, N'-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-41-7 CAPLUS
CN Urea, N-[5-chloro-4-(cyclopropylmethoxy)-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]-N'-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-49-5 CAPLUS
CN Acetamide, N-[5-chloro-4-(cyclopropylmethoxy)-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-50-8 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-51-9 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-4-methylphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-52-0 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-(2-pyrazinyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-53-1 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-4-(2-pyrazinyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-54-2 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-4-(2-pyridinyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-55-3 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-(2-pyridinyl)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-56-4 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[(3-endo)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(2-pyrazinyl)phenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-57-5 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[(3-endo)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(2-pyridinyl)phenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-58-6 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[(3-endo)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-60-0 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[(3-endo)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 868408-61-1 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[(3-endo)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-62-2 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[(3-endo)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-63-3 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[(1E)-3-[(3-endo)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxy-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-64-4 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[(8-anti)-8-[(4-fluorophenyl)amino]-3-azabicyclo[3.2.1]oct-3-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-67-7 CAPLUS
CN Urea, N-[5-chloro-2-[(1E)-3-[(9-anti)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-71-3 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[(9-anti)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-72-4 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[(9-anti)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-73-5 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[(7-endo)-7-[(4-fluorophenyl)amino]-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-76-8 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[(7-endo)-7-[(4-fluorophenyl)amino]-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-77-9 CAPLUS
CN Urea, N'-[5-chloro-2-[(1E)-3-[(7-endo)-7-[(4-fluorophenyl)amino]-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-N,N-

dimethyl- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-79-1 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[(1E)-3-[(7-endo)-7-[(4-fluorophenyl)amino]-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-N,N-dimethyl-4-(trifluoromethoxy)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-80-4 CAPLUS
CN Acetamide, N-[5-chloro-4-fluoro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-81-5 CAPLUS
CN Acetamide, N-[5-chloro-4-fluoro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-83-7 CAPLUS
CN 4,6-Diazaspiro[2.4]heptane-5,7-dione, 6-[5-chloro-4-fluoro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-86-0 CAPLUS
CN 4,6-Diazaspiro[2.4]heptane-5,7-dione, 6-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-90-6 CAPLUS
CN 4,6-Diazaspiro[2.4]heptane-5,7-dione, 6-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-94-0 CAPLUS
CN 2,4-Imidazolidinedione, 3-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethyl)phenyl]-5-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-98-4 CAPLUS
CN 2,4-Imidazolidinedione, 3-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]-5-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868409-01-2 CAPLUS
CN 2,4-Imidazolidinedione, 3-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-5-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 868547-42-6 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[(9-syn)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868547-44-8 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[(9-syn)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 868407-35-6, 3-(2-Amino-4-chlorophenyl)-1-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]prop-2-enone 868407-79-8, N-[5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]-4-methoxyphenyl]acetamide hydrochloride 868408-33-7, (E)-3-(2-Amino-4-chloro-5-methoxyphenyl)-1-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]prop-2-enone 1046118-50-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of bicyclic heterocycles as CCR-1 antagonists)

RN 868407-35-6 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chlorophenyl)-1-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]- (CA INDEX NAME)



RN 868407-79-8 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-33-7 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chloro-5-methoxyphenyl)-1-[9-[(4-

fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1046118-50-6 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]-N,N-dimethyl-4-(trifluoromethoxy)- (CA INDEX NAME)

Double bond geometry as shown.



IT 868406-30-8P, (E)-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]carbamic acid tert-butyl ester 868406-31-9P, (E)-[5-Chloro-2-[3-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl]phenyl]carbamic acid tert-butyl ester 868406-32-0P, (E)-3-(2-Amino-4-chlorophenyl)-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]prop-2-enone 868406-35-3P, (E)-2-Chloro-N-[5-chloro-2-[3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]ethanamide hydrochloride 868406-49-9P, (E)-3-(2-Amino-4-chlorophenyl)-1-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]prop-2-enone 868406-58-0P, (E)-3-(2-Amino-4-chloro-5-methoxyphenyl)-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]prop-2-enone 868406-76-2P, (E)-3-(4-Chloro-5-ethoxy-2-nitrophenyl)-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]prop-2-enone 868406-77-3P, (E)-3-(2-Amino-4-chloro-5-ethoxyphenyl)-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]prop-2-enone 868406-84-2P, (E)-3-(2-Amino-4-chloro-5-trifluoromethoxyphenyl)-1-[3-(4-fluorobenzyl)-

3,8-diazabicyclo[3.2.1]oct-8-yl]prop-2-enone 868406-96-6P, (E)-3-(2-Amino-4-chloro-5-methylphenyl)-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]prop-2-enone 868407-10-7P, (E)-3-(5-Bromo-4-chloro-2-nitrophenyl)-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]prop-2-enone 868407-11-8P, (E)-3-(2-Amino-5-bromo-4-chlorophenyl)-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]prop-2-enone 868407-12-9P, N-[4-Bromo-5-chloro-2-[(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl]phenyl]acetamide 868407-23-2P, (E)-3-[4-Chloro-2-nitro-5-(pyridin-3-yl)phenyl]-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]prop-2-enone 868407-24-3P, (E)-3-[2-Amino-4-chloro-5-(pyridin-3-yl)phenyl]-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]prop-2-enone 868407-32-3P, (E)-[5-Chloro-2-[3-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]carbamic acid tert-butyl ester 868407-33-4P, (E)-3-(2-Amino-4-chlorophenyl)-1-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]prop-2-enone 868407-38-9P, (E)-2-Chloro-N-[5-chloro-2-[3-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]ethanamide 868407-51-6P, (E)-9-[3-[4-Chloro-2-(2,2,2-trifluoroacetylamino)phenyl]acryloyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-52-7P, (E)-9-[3-(2-Amino-4-chlorophenyl)acryloyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-53-8P, (E)-9-[3-(2-Acetylamino-4-chlorophenyl)acryloyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-55-0P, (E)-9-[3-[4-Chloro-2-(2-dimethylaminoacetylamino)phenyl]acryloyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-57-2P, (E)-9-[3-[4-Chloro-2-[(methylsulfonyl)amino]phenyl]acryloyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-59-4P, 9-[(E)-3-(4-Chloro-2-ureidophenyl)-2-propenoyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-61-8P, (E)-9-[3-(2-Acetylamino-4-chloro-5-fluorophenyl)acryloyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-65-2P, [5-Chloro-2-[(E)-3-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]carbamic acid tert-butyl ester 868407-66-3P, (E)-3-(2-Amino-4-chlorophenyl)-1-[3-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]prop-2-enone 868407-70-9P, (E)-9-[3-(2-Amino-4-chloro-5-methoxyphenyl)acryloyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-71-0P, (E)-9-[3-(2-Acetylamino-4-chloro-5-methoxyphenyl)acryloyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-73-2P, 9-[(E)-3-[4-Chloro-2-[(methylsulfonyl)amino]-5-methoxyphenyl]-2-propenoyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-75-4P, 9-[(E)-3-(4-Chloro-5-methoxy-2-ureidophenyl)-2-propenoyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-77-6P, 9-[(E)-3-[4-Chloro-2-(2-dimethylaminoacetylamino)-5-methoxyphenyl]acryloyl]-7-(4-fluorobenzyl)-3,7,9-

triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-87-8P 868407-88-9P, 9-[(E)-3-[2-(Acetylamino)-4-chloro-5-methylphenyl]-2-propenoyl]-7-(4-fluorobenzyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester 868407-93-6P, (E)-3-(2-Amino-4-chloro-5-methylphenyl)-1-[9-(4-fluorobenzyl)-7-methyl-3,7,9-triazabicyclo[3.3.1]non-3-yl]prop-2-enone 868408-12-2P, (E)-[5-Chloro-2-[3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl]phenyl]carbamic acid tert-butyl ester 868408-13-3P, (E)-3-(2-Amino-4-chlorophenyl)-1-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]prop-2-enone 868408-15-5P, (E)-[5-Chloro-2-[3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl]phenyl]carbamic acid tert-butyl ester 868408-16-6P, (E)-3-(2-Amino-4-chlorophenyl)-1-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]prop-2-enone 868408-35-9P, (E)-3-(2-Amino-4-chloro-5-trifluoromethoxyphenyl)-1-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]prop-2-enone 868408-48-4P, (E)-3-[2-Amino-4-chloro-5-(cyclopropylmethoxy)phenyl]-1-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]prop-2-enone 868408-59-7P, (E)-3-(2-Amino-4-chloro-5-methoxyphenyl)-1-[(1R,3R,5S)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]prop-2-enone 868408-70-2P, (E)-3-(2-Amino-4-chloro-5-trifluoromethoxyphenyl)-1-[(1S,5R,9S)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]prop-2-enone 868408-78-0P, (E)-3-(2-Amino-4-chloro-5-methoxyphenyl)-1-[(1S,5R,7S)-7-[(4-fluorophenyl)amino]-3-oxa-9-azabicyclo[3.3.1]non-9-yl]prop-2-enone 868547-43-7P, (E)-3-(2-Amino-4-chloro-5-trifluoromethoxyphenyl)-1-[(1S,5R,9R)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]prop-2-enone 1046117-77-4P 1046117-79-6P 1046117-82-1P 1046117-94-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic heterocycles as CCR-1 antagonists)

RN 868406-30-8 CAPLUS
CN Carbamic acid, [5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propenyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-31-9 CAPLUS
CN Carbamic acid, [5-chloro-2-[(1E)-3-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxo-1-propenyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-32-0 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chlorophenyl)-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-35-3 CAPLUS
CN Acetamide, 2-chloro-N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-49-9 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chlorophenyl)-1-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-58-0 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chloro-5-methoxyphenyl)-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-76-2 CAPLUS
CN 2-Propen-1-one, 3-(4-chloro-5-ethoxy-2-nitrophenyl)-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-77-3 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chloro-5-ethoxyphenyl)-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-84-2 CAPLUS
CN 2-Propen-1-one, 3-[2-amino-4-chloro-5-(trifluoromethoxy)phenyl]-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868406-96-6 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chloro-5-methylphenyl)-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-10-7 CAPLUS

CN 2-Propen-1-one, 3-(5-bromo-4-chloro-2-nitrophenyl)-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-11-8 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-5-bromo-4-chlorophenyl)-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-12-9 CAPLUS
CN Acetamide, N-[4-bromo-5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-23-2 CAPLUS
CN 2-Propen-1-one, 3-[4-chloro-2-nitro-5-(3-pyridinyl)phenyl]-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-24-3 CAPLUS
CN 2-Propen-1-one, 3-[2-amino-4-chloro-5-(3-pyridinyl)phenyl]-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-32-3 CAPLUS
CN Carbamic acid, [5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propenyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-33-4 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chlorophenyl)-1-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-38-9 CAPLUS
CN Acetamide, 2-chloro-N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-51-6 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-[4-chloro-2-[(2,2,2-trifluoroacetyl)amino]phenyl]-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-52-7 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-(2-amino-4-chlorophenyl)-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-53-8 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-[2-(acetylamino)-4-chlorophenyl]-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-55-0 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-[4-chloro-2-[[2-(dimethylamino)acetyl]amino]phenyl]-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-57-2 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-[4-chloro-2-[(methylsulfonyl)amino]phenyl]-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-59-4 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-[2-[(aminocarbonyl)amino]-4-chlorophenyl]-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-61-8 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-[2-(acetylamino)-4-chloro-5-fluorophenyl]-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-65-2 CAPLUS
CN Carbamic acid, [5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propenyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-66-3 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chlorophenyl)-1-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-70-9 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-(2-amino-4-chloro-5-methoxyphenyl)-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-71-0 CAPLUS

CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-[2-(acetylamino)-4-chloro-5-methoxyphenyl]-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-73-2 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-[4-chloro-5-methoxy-2-[(methylsulfonyl)amino]phenyl]-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-75-4 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-[2-[(aminocarbonyl)amino]-4-chloro-5-methoxyphenyl]-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-77-6 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-[4-chloro-2-[[2-(dimethylamino)acetyl]amino]-5-methoxyphenyl]-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester, hydrochloride (1:2) (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-87-8 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-(2-amino-4-chloro-5-methylphenyl)-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-88-9 CAPLUS
CN 3,7,9-Triazabicyclo[3.3.1]nonane-3-carboxylic acid, 9-[(2E)-3-[2-(acetylamino)-4-chloro-5-methylphenyl]-1-oxo-2-propen-1-yl]-7-[(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 868407-93-6 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chloro-5-methylphenyl)-1-[9-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-3-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-12-2 CAPLUS
CN Carbamic acid, [5-chloro-2-[(1E)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxo-1-propenyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-13-3 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chlorophenyl)-1-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-15-5 CAPLUS
CN Carbamic acid, [5-chloro-2-[(1E)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propenyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-16-6 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chlorophenyl)-1-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-35-9 CAPLUS
CN 2-Propen-1-one, 3-[2-amino-4-chloro-5-(trifluoromethoxy)phenyl]-1-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-48-4 CAPLUS
CN 2-Propen-1-one, 3-[2-amino-4-chloro-5-(cyclopropylmethoxy)phenyl]-1-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868408-59-7 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chloro-5-methoxyphenyl)-1-[(3-endo)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-70-2 CAPLUS
CN 2-Propen-1-one, 3-[2-amino-4-chloro-5-(trifluoromethoxy)phenyl]-1-[(9-syn)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868408-78-0 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chloro-5-methoxyphenyl)-1-[(7-endo)-7-[(4-fluorophenyl)amino]-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 868547-43-7 CAPLUS
CN 2-Propen-1-one, 3-[2-amino-4-chloro-5-(trifluoromethoxy)phenyl]-1-[(9-anti)-9-[(4-fluorophenyl)amino]-3-oxa-7-azabicyclo[3.3.1]non-7-yl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 1046117-77-4 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chloro-5-methylphenyl)-1-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1046117-79-6 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chloro-5-methoxyphenyl)-1-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]non-9-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1046117-82-1 CAPLUS
CN 2-Propen-1-one, 3-(2-amino-4-chloro-5-methoxyphenyl)-1-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1046117-94-5 CAPLUS
CN 2-Propen-1-one, 3-[2-amino-4-chloro-5-(trifluoromethoxy)phenyl]-1-[(3-endo)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT:	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1144476 CAPLUS
DOCUMENT NUMBER: 144:51547
TITLE: Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis
AUTHOR(S): Revesz, Laszlo; Bollbuck, Birgit; Buhl, Thomas; Eder, Joerg; Esser, Ronald; Feifel, Roland; Heng, Richard; Hiestand, Peter; Jachez-Demange, Benedicte; Loetscher, Pius; Sparrer, Helmut; Schlapbach, Achim; Waelchli, Rudolf
CORPORATE SOURCE: Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Autoimmunity and Transplantation, Basel, CH-4002, Switz.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(23), 5160-5164
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:51547
AB Cinnamides as novel CCR1 antagonist chemotypes are described with high affinity to human and rodent receptors. Two compds., (2R)-1-[3-[2-[(aminocarbonyl)amino]-4-chlorophenyl]-1-oxo-2-propenyl]-4-[(4-fluorophenyl)methyl]-2-(methyl)piperazine and N-[5-chloro-2-[3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octyl]-3-oxo-1-propenyl]phenyl]-2-(dimethylamino)acetamide, showed oral activity in the mouse collagen induced arthritis.
IT 868406-34-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of N-[chloro[[(fluorobenzyl)-3,8-diazabicyclo[3.2.1]octyl]oxopropenyl]phenyl]amino acetamide and study of its activity as orally active CCR1 antagonist in collagen-induced arthritis)
RN 868406-34-2 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)

Double bond geometry as shown.



IT 868406-60-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of [(fluorophenyl)methyl]piperazine derivs. and study of their

activity as orally active CCR1 antagonists in collagen-induced arthritis)

RN 868406-60-4 CAPLUS

CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]-4-methoxyphenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 868406-32-0P 868524-41-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of [(fluorophenyl)methyl]piperazine derivs. and study of their activity as orally active CCR1 antagonists in collagen-induced arthritis model)

RN 868406-32-0 CAPLUS

CN 2-Propen-1-one, 3-(2-amino-4-chlorophenyl)-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 868524-41-8 CAPLUS

CN Acetamide, 2-chloro-N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 871324-92-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of [[[chloro(acetylamino)phenoxy]methyl]carbonyl](fluorobenzyl)-2,5-diazabicyclo[2.2.1]heptane derivs. and study of their activity as orally active CCR1 antagonists in collagen-induced arthritis)
RN 871324-92-4 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[(1R,4R)-5-[(4-fluorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 868406-29-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of [[[chloro(acetylamino)phenoxy]methyl]carbonyl](fluorobenzyl)-3,8-diazabicyclo[3.2.1]octane derivs. and study of their activity as orally active CCR1 antagonists in collagen-induced arthritis)
RN 868406-29-5 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



IT 868406-53-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of [[[chloro(acetylamino)phenoxy]methyl]carbonyl](fluorobenzyl) diazabicyclooctane derivs. and study of their activity as orally active CCR1 antagonists in collagen-induced arthritis)
RN 868406-53-5 CAPLUS
CN Acetamide, N-[5-chloro-2-[(1E)-3-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:962024 CAPLUS
DOCUMENT NUMBER: 143:248412
TITLE: Preparation of piperazine derivatives as CCR1 antagonists for the treatment of endometriosis
INVENTOR(S): Kaufmann, Ulrike
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany; Horuk, Richard
SOURCE: PCT Int. Appl., 291 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079769	A2	20050901	WO 2005-EP2036	20050223
WO 2005079769	A3	20070104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005215156	A1	20050901	AU 2005-215156	20050223
CA 2556423	A1	20050901	CA 2005-2556423	20050223
EP 1727526	A2	20061206	EP 2005-715567	20050223
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
BR 2005007985	A	20070508	BR 2005-7985	20050223
JP 2007523126	T	20070816	JP 2006-553572	20050223
CN 101090723	A	20071219	CN 2005-80012936	20050223
US 20080119471	A1	20080522	US 2005-64116	20050223
MX 2006009687	A	20061030	MX 2006-9687	20060824
IN 2006DN04855	A	20070817	IN 2006-DN4855	20060824
NO 2006004298	A	20061124	NO 2006-4298	20060922
KR 2007033961	A	20070327	KR 2006-719708	20060922
ZA 2006007970	A	20081231	ZA 2006-7970	20060922

PRIORITY APPLN. INFO.:
EP 2004-90065 A 20040224
US 2004-548950P P 20040302
WO 2005-EP2036 W 20050223

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:248412; MARPAT 143:248412
GI



I



II

AB The use is claimed of piperazine derivs. (shown as I; variables defined below; e.g. (2R,5S)-1-[[(4-chlorophenoxy)methyl]carbonyl]-2-methyl-4-(4-fluorobenzyl)-5-[(hydroxy)methyl]piperazine (shown as II)) for the production of a medicament for the treatment of endometriosis in humans wherein the treatment comprises administering to a human female in need of such treatment a therapeutically effective amount of said compound Compds. I inhibit the activity of the chemokines MIP-1α and RANTES and thus are antagonists of human chemokine "C-C" receptor 1 (CCR1). For I: R1a is ≥1 substituents = oxo, halo, (C1-C8)alkyl, (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8) alkyl, (C3-C10)cycloalkylamino(C1-C8)alkyl, [(C3-C10)cycloalkyl(C1-C8) alkyl]amino(C1-C8)alkyl, halo(C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, et al.; R2 is ≥1 substituents = H, hydroxy, hydroxysulfonyl, halo, (C1-C8)alkyl, mercapto, mercapto(C1-C8)alkyl, (C1-C8)alkylthio, (C1-C8)alkylsulfinyl, (C1-C8)alkylsulfonyl, (C1-C8)alkylthio(C1-C8)alkyl, (C1-C8)alkylsulfinyl(C1-C8)alkyl, (C1-C8) alkylsulfonyl(C1-C8)alkyl, et al.; R3 is a carbocyclic 3- to 15-membered ring system substituted by ≥1 H, hydroxy, hydroxysulfonyl, halo, (C1-C8)alkyl, mercapto, mercapto(C1-C8)alkyl, (C1-C8)alkylthio, et al.; R4 is -O-, -N(R7)-, -C(R8)2- or a bond; R5 is an (C1-C8) alkylene chain or an (C1-C8) alkylidene chain, or, if R4 is a bond, R5 is an (C1-C8) alkylidene chain (un)substituted by (un)substituted Ph or naphthyl or -N(R7)2; or R4 and R5 together are -HC:CH-; R6 is -C(O)-, -C(S)-, -CH2- or a bond; addnl. details are given in the claims. Although the methods of preparation are not claimed, 16 example prepns. and characterization data for a large number of I are included. For example, II was prepared (79 % yield) by N-acylation of (2R,5S)-1-(4-fluorobenzyl)-2-[(hydroxy)methyl]-5-methylpiperazine by 4-chlorophenoxyacetyl chloride.

IT 217644-61-6P, 4'-(4-Fluorobenzyl)-1'-[[(4-chlorophenoxy)methyl]carbonyl]spiro[cyclopropane-1,2'-piperazine] 863402-72-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperazine derivs. as CCR1 antagonists for treatment of endometriosis)

RN 217644-61-6 CAPLUS

CN Ethanone, 2-(4-chlorophenoxy)-1-[7-[(4-fluorophenyl)methyl]-4,7-

diazaspiro[2.5]oct-4-yl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 863402-72-6 CAPLUS
CN 4,7-Diazaspiro[2.5]octane, 4-[(4-chlorophenoxy)acetyl]-7-[(4-fluorophenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:1015876 CAPLUS
DOCUMENT NUMBER: 142:23273
TITLE: Preparation of pyrazolyl phenyl urea derivatives as inhibitors of p38 kinase and/or tumor necrosis factor (TNF) inhibitors for the treatment of inflammations
INVENTOR(S): Borcherding, David R.; Gross, Alexandre; Shum, Patrick Wai-Kwok; Willard, Nicole; Freed, Brian S.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004100946	A1	20041125	WO 2004-US13875	20040505
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004238241	A1	20041125	AU 2004-238241	20040505
CA 2524043	A1	20041125	CA 2004-2524043	20040505
CA 2524043	C	20091229		
EP 1622610	A1	20060208	EP 2004-751319	20040505
EP 1622610	B1	20061220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009991	A	20060509	BR 2004-9991	20040505
AT 348610	T	20070115	AT 2004-751319	20040505
JP 2007502324	T	20070208	JP 2006-532565	20040505
PT 1622610	E	20070228	PT 2004-751319	20040505
ES 2277271	T3	20070701	ES 2004-751319	20040505
US 20060063796	A1	20060323	US 2005-264063	20051101
US 7541368	B2	20090602		

PRIORITY APPLN. INFO.: US 2003-468285P P 20030506
WO 2004-US13875 W 20040505
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 142:23273
GI



I



II

AB Title compds. I [Wherein R1 = (cyclo)alkyl, (un)substituted aryl or pyridyl; R2 = (un)substituted (cyclo)alkyl; X = C(O), C(O)CH2, S(O)2, or NHC(O); A = (un)substituted alk(en/yn)yl; B = (CH2)n; n = 0 or 2; et al., or pharmaceutically acceptable salts, solvates or ester prodrugs thereof; or ester prodrugs of such salts or solvates], useful as inhibitors of p38 kinase and/or tumor necrosis factor (TNF), were prepared Thus, condensation of 4-methylenepiperidine hydrochloride with 2,4-dimethoxybenzoyl chloride followed by addition reaction with 9-BBN and subsequent Pd-catalyzed coupling with m-bromoaniline gave an aniline derivative This compound underwent addition
reaction with 5-isocyanato-3-tert-butyl-1-(4-methylphenyl)pyrazole to afford urea II. Compds. I were tested in several biol. assays. E.g., I showed 50% inhibition at the concns. of 0.3-10000 nM in the p38 cascade assay, at the concns. of 10-50000 nM in the murine p38 assay, and at the concns. of 10-50000 nM in the LPS-induced TNFα assay.
Pharmaceutical compns. comprising I are useful in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF), such as asthma and joint inflammation.

IT 1082348-50-2 1082348-81-9 1082353-65-8
1082355-87-0 1082357-16-1 1082362-36-4
1082362-75-1 1175137-11-7
RL: PRPH (Prophetic)
(Preparation of pyrazolyl phenyl urea derivatives as inhibitors of p38 kinase and/or tumor necrosis factor (TNF) inhibitors for the treatment of inflammations)

RN 1082348-50-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082348-81-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082353-65-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082355-87-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082357-16-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082362-36-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1082362-75-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1175137-11-7 CAPLUS
CN Urea, N-[3-[[8-[3-(2,2-difluoro-1,3-benzodioxol-5-yl)-1-oxo-2-propen-1-yl]-8-azabicyclo[3.2.1]oct-3-yl]methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



IT 799291-19-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of pyrazolyl Ph urea derivs. as inhibitors of p38 kinase and/or tumor necrosis factor (TNF))
RN 799291-19-3 CAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[3-[[8-[2-(phenylamino)acetyl]-8-azabicyclo[3.2.1]oct-3-yl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT:	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:80685 CAPLUS
DOCUMENT NUMBER: 140:146011
TITLE: Preparation of bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor
INVENTOR(S): Blumberg, Laura Cook; Brown, Matthew Frank; Hayward, Matthew Merrill; Poss, Christopher Stanley
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009588	A1	20040129	WO 2003-IB3155	20030707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492110	A1	20040129	CA 2003-2492110	20030707
AU 2003281527	A1	20040209	AU 2003-281527	20030707
BR 2003012699	A	20050426	BR 2003-12699	20030707
EP 1525201	A1	20050427	EP 2003-741007	20030707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1668614	A	20050914	CN 2003-817005	20030707
JP 2005533845	T	20051110	JP 2004-522638	20030707
US 20040063688	A1	20040401	US 2003-616843	20030708
IN 2004DN04155	A	20050401	IN 2004-DN4155	20041228
MX 2005000757	A	20050419	MX 2005-757	20050118

PRIORITY APPLN. INFO.:	US 2002-397263P	P	20020718
	WO 2003-IB3155	W	20030707

OTHER SOURCE(S): MARPAT 140:146011
GI



I

AB The title compds. [I; a = 1-5; b = 0-4; c = 0-1; Q = alkyl; W = aryl,

heteroaryl; Y = O, NH, N(alkyl); Z = O, NH, N(alkyl), N(acetyl); R1 = H, halo, CN, NO2, etc.; R2, R3 = H, alkyl, haloalkyl; R4 = alkylene, (CH2)xO(CH2)y (wherein x, y = 1-2); R5 = H, halo, alkyl, etc.; R6 = H, halo, alkyl, etc.], useful as potent and selective inhibitors of MIP-1α(CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes), were prepared E.g., a multi-step synthesis of (trans)-5-chloro-2-{2-[3-(4-fluorophenoxy)-8-aza-bicyclo[3.2.1]oct-8-yl]-2-oxoethoxy}benzamide was given. All exemplified compds. I had IC50 of <10 μM in the chemotaxis assay. Pharmaceutical composition comprising the compound I is claimed.

IT 652147-27-8P 652147-91-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of bicyclic piperidine derivs. as antagonists of the CCR1 chemokine receptor)

RN 652147-27-8 CAPLUS
CN Ethanone, 2-[4-chloro-2-(hydroxymethyl)phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-91-6 CAPLUS
CN Acetic acid, 2-[[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]methoxy]- (CA INDEX NAME)

Relative stereochemistry.



IT 652146-57-1P 652146-59-3P 652146-62-8P
652146-64-0P 652146-66-2P 652146-69-5P
652146-71-9P 652146-73-1P 652146-75-3P
652146-77-5P 652146-79-7P 652146-80-0P
652146-81-1P 652146-82-2P 652146-83-3P
652146-85-5P 652146-86-6P 652146-87-7P
652146-90-2P 652146-92-4P 652146-94-6P
652146-95-7P 652146-96-8P 652147-01-8P

652147-02-9P 652147-04-1P 652147-06-3P
652147-08-5P 652147-10-9P 652147-11-0P
652147-13-2P 652147-15-4P 652147-17-6P
652147-18-7P 652147-19-8P 652147-21-2P
652147-23-4P 652147-25-6P 652147-29-0P
652147-31-4P 652147-33-6P 652147-35-8P
652147-37-0P 652147-39-2P 652147-40-5P
652147-41-6P 652147-42-7P 652147-43-8P
652147-44-9P 652147-45-0P 652147-46-1P
652147-47-2P 652147-48-3P 652147-49-4P
652147-50-7P 652147-83-6P 652147-85-8P
652147-87-0P 652147-89-2P 652147-90-5P
652147-92-7P 652147-94-9P 652147-95-0P
652147-96-1P 652147-97-2P 652147-98-3P
652148-22-6P 652148-23-7P 652148-36-2P
653599-80-5P 653599-81-6P 653599-83-8P
653599-84-9P 653599-85-0P 653599-86-1P
653599-87-2P 653599-88-3P 653599-90-7P
653599-92-9P 653600-08-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic piperidine derivs. as antagonists of the CCR1 chemokine receptor)

RN 652146-57-1 CAPLUS
CN Benzamide, 5-chloro-2-[2-[(3-endo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-59-3 CAPLUS
CN Urea, N-[5-chloro-2-[2-[(3-endo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-62-8 CAPLUS
CN Benzeneacetic acid, 5-chloro-2-[2-[(3-endo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-64-0 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(3-endo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-66-2 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(3-endo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-69-5 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-71-9 CAPLUS
CN Benzamide, 2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-4-methoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-73-1 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-75-3 CAPLUS
CN Glycine, N-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 652146-77-5 CAPLUS
CN Butanamide, N-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]-3-hydroxy-3-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-79-7 CAPLUS
CN Benzamide, N-[2-[(aminocarbonyl)amino]ethyl]-5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-80-0 CAPLUS
CN Benzamide, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-81-1 CAPLUS
CN Ethanone, 2-[4-chloro-2-[[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-82-2 CAPLUS
CN Benzamide, N-(2-aminoethyl)-5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-83-3 CAPLUS
CN Ethanone, 2-[4-chloro-2-(4-morpholinylcarbonyl)phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-85-5 CAPLUS
CN Benzamide, 5-chloro-N-[2-(dimethylamino)ethyl]-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-86-6 CAPLUS
CN L-Proline, 1-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoyl]-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-87-7 CAPLUS
CN Ethanone, 2-[4-chloro-2-[[(3R)-3-hydroxy-1-pyrrolidinyl]carbonyl]phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX

NAME)

Absolute stereochemistry.



RN 652146-90-2 CAPLUS
CN Benzamide, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-2-pyridinyl- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-92-4 CAPLUS
CN Methanesulfonamide, N-[2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-94-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2-[2-[3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoyl]-4-hydroxy-, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-95-7 CAPLUS
CN Benzamide, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652146-96-8 CAPLUS
CN Ethanone, 2-[4-chloro-2-(1-hydroxy-1-methylethyl)phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-01-8 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-02-9 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-04-1 CAPLUS
CN Benzeneacetic acid, 5-bromo-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-06-3 CAPLUS
CN Benzeneacetamide, 5-bromo-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-08-5 CAPLUS
CN Benzeneacetamide, 5-bromo-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-10-9 CAPLUS
CN Benzenepropanoic acid, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-11-0 CAPLUS
CN Benzenepropanamide, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-13-2 CAPLUS
CN Ethanone, 1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-15-4 CAPLUS
CN Ethanone, 2-(4-bromophenoxy)-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-17-6 CAPLUS
CN Ethanone, 1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-[4-(trifluoromethyl)phenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-18-7 CAPLUS
CN Ethanone, 1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-(4-methylphenoxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-19-8 CAPLUS
CN Ethanone, 2-(4-chlorophenoxy)-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-21-2 CAPLUS
CN Ethanone, 2-(2-acetyl-4-chlorophenoxy)-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-23-4 CAPLUS
CN Benzamide, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-25-6 CAPLUS
CN Benzamide, 5-bromo-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-29-0 CAPLUS
CN Ethanone, 2-[4-bromo-2-(hydroxymethyl)phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-31-4 CAPLUS
CN Ethanone, 2-(4-chloro-2-hydroxyphenoxy)-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-33-6 CAPLUS
CN Acetic acid, 2-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-35-8 CAPLUS
CN Ethanone, 2-(4-bromo-2-hydroxyphenoxy)-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-37-0 CAPLUS
CN Benzamide, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-39-2 CAPLUS
CN Benzamide, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(3-hydroxypropyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-40-5 CAPLUS
CN L-Proline, 1-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 652147-41-6 CAPLUS
CN L-Homoserine, O-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 652147-42-7 CAPLUS
CN Acetamide, N-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-43-8 CAPLUS
CN Methanesulfonamide, N-[5-bromo-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-44-9 CAPLUS
CN Acetamide, N-[5-bromo-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-45-0 CAPLUS
CN Propanamide, N-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]-2-hydroxy-2-methyl-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-46-1 CAPLUS
CN Acetamide, N-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]-2-hydroxy-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-47-2 CAPLUS
CN Carbamic acid, [5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl](methylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 652147-48-3 CAPLUS
CN Cyclopropanecarboxamide, N-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]-1-hydroxy-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-49-4 CAPLUS
CN Acetamide, N-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]-2-methoxy-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-50-7 CAPLUS
CN Benzenemethanesulfonic acid, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-83-6 CAPLUS
CN Benzamide, 5-chloro-2-[2-[(3-exo)-3-[(4-fluorophenyl)amino]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-85-8 CAPLUS
CN Benzamide, 5-chloro-2-[2-[(7-endo)-7-(4-fluorophenoxy)-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-87-0 CAPLUS
CN Benzeneacetic acid, 5-chloro-2-[2-[(7-endo)-7-(4-fluorophenoxy)-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-89-2 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(7-endo)-7-(4-fluorophenoxy)-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-90-5 CAPLUS
CN Acetamide, 2-[[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]methoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-92-7 CAPLUS
CN Acetamide, 2-[[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]methoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-94-9 CAPLUS
CN Acetamide, 2-[[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]methoxy]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-95-0 CAPLUS
CN Ethanone, 2-[4-chloro-2-[(2H-tetrazol-5-ylamino)methyl]phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-96-1 CAPLUS
CN Ethanone, 2-[2-[(5-amino-2H-tetrazol-2-yl)methyl]-4-chlorophenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-97-2 CAPLUS
CN Ethanone, 2-[2-[(5-amino-1H-tetrazol-1-yl)methyl]-4-chlorophenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-98-3 CAPLUS
CN Ethanone, 2-[4-chloro-2-(2H-tetrazol-5-ylmethyl)phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652148-22-6 CAPLUS
CN Ethanone, 2-[4-chloro-2-(2H-tetrazol-5-yl)phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652148-23-7 CAPLUS
CN Ethanone, 2-[4-chloro-2-(methylsulfonyl)phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652148-36-2 CAPLUS
CN Benzoic acid, 4-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 653599-80-5 CAPLUS
CN Benzamide, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 653599-81-6 CAPLUS
CN Urea, N-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 653599-83-8 CAPLUS
CN Ethanone, 2-[4-chloro-2-[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 653599-84-9 CAPLUS
CN Ethanone, 2-[4-chloro-2-[[(3S)-3-hydroxy-1-pyrrolidinyl]carbonyl]phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 653599-85-0 CAPLUS
CN D-Proline, 1-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoyl]-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 653599-86-1 CAPLUS
CN L-Proline, 1-[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoyl]-4-hydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 653599-87-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2-[2-[3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoyl]-4-hydroxy-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 653599-88-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2-[2-[3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 653599-90-7 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 653599-92-9 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 653600-08-9 CAPLUS
CN Benzeneacetic acid, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



IT 652148-18-0P 652148-19-1P 652148-20-4P
652148-21-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic piperidine derivs. as antagonists of the CCR1 chemokine receptor)

RN 652148-18-0 CAPLUS
CN Benzaldehyde, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 652148-19-1 CAPLUS
CN Acetic acid, 2-[[5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]methoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 652148-20-4 CAPLUS
CN Ethanone, 2-[4-chloro-2-(chloromethyl)phenoxy]-1-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 652148-21-5 CAPLUS
CN Benzeneacetonitrile, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:964330 CAPLUS
DOCUMENT NUMBER: 138:39295
TITLE: Preparation of heterocyclic compounds as Rho-kinase inhibitors
INVENTOR(S): Imazaki, Naonori; Kitano, Masafumi; Ohashi, Naohito; Matsui, Kazuki
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Company, Limited, Japan
SOURCE: PCT Int. Appl., 425 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100833	A1	20021219	WO 2002-JP5609	20020606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002306284	A1	20021223	AU 2002-306284	20020606
EP 1403255	A1	20040331	EP 2002-733352	20020606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040138286	A1	20040715	US 2003-480526	20031212
US 7199147	B2	20070403		

PRIORITY APPLN. INFO.: JP 2001-176826 A 20010612
JP 2001-398992 A 20011228
WO 2002-JP5609 W 20020606
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 138:39295
GI



I

AB The title compds. I [wherein one to four groups represented by the general formula R1-X are present and may be the same or different from each other; A is a saturated or unsatd. five-membered heterocycle; X is a single bond, N(R3), O, S, or the like; R1 is hydrogen, halogeno, nitro, carboxyl, substituted or unsubstituted alkyl, or the like; R2 is hydrogen, halogeno, nitro, carboxyl, substituted or unsubstituted alkyl, or the like; and R3

is hydrogen, substituted or unsubstituted alkyl, or the like] are prepared N-(1-Benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride monohydrate in vitro showed IC50 of 0.4 μL/mL against Rho-kinase.

IT 478838-06-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as Rho-kinase inhibitors)

RN 478838-06-1 CAPLUS

CN Ethanone, 1-[3-(1H-indazol-5-ylamino)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 36 THERE ARE 36 CAPLUS RECORDS THAT CITE THIS RECORD (42 CITINGS)

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:314940 CAPLUS
DOCUMENT NUMBER: 136:340711
TITLE: Bridged piperazine derivatives, specifically 3,8-diazabicyclo[3.2.1]octane, 8-azabicyclo[3.2.1]octane, 2,5-diazabicyclo[2.2.2]octane, and 3,9-diazabicyclo[3.3.1]nonane derivatives, useful as inhibitors of chemokines binding to CCR1 receptors, for treating inflammation and other immune disorders.
INVENTOR(S): Blumberg, Laura Cook; Brown, Matthew Frank; Glaude, Ronald Paul; Poss, Christopher Stanley
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032901	A2	20020425	WO 2001-IB1844	20011004
WO 2002032901	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2423789	A1	20020425	CA 2001-2423789	20011004
AU 2001092160	A	20020429	AU 2001-92160	20011004
EP 1326867	A2	20030716	EP 2001-972389	20011004
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300189	A	20031015	EE 2003-189	20011004
BR 2001014697	A	20031118	BR 2001-14697	20011004
HU 2003001442	A2	20031229	HU 2003-1442	20011004
HU 2003001442	A3	20070328		
JP 2004511558	T	20040415	JP 2002-536283	20011004
NZ 524742	A	20041224	NZ 2001-524742	20011004
US 20020119961	A1	20020829	US 2001-972177	20011005
IN 2003MN00309	A	20050211	IN 2003-MN309	20030317
ZA 2003002157	A	20040422	ZA 2003-2157	20030318
BG 107655	A	20040130	BG 2003-107655	20030320
NO 2003001572	A	20030610	NO 2003-1572	20030408
MX 2003003475	A	20030714	MX 2003-3475	20030416

PRIORITY APPLN. INFO.: US 2000-241804P P 20001019
WO 2001-IB1844 W 20011004
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 136:340711
GI



I



II

AB Compds. I and their pharmaceutically acceptable salts, useful for treatment of inflammation and other immune disorders, are disclosed [wherein: n = 1-5; m = 1-5; q = 0-1; a, b, c = (CH2)0-4 (independently); a, b, and c cannot all be null; if a and/or c is not null, then b must be null; W = CH or N; X = CO, C(S), or CH2; Y = CH2; Z = O, (un)substituted NH or (un)substituted CH2; R = certain (un)substituted (hetero)aryl or (hetero)cycloalkyl; R1 = (independently) H, OH, SO3H, halo, alkyl, SH, CF3, wide variety of other substituents]. The compds. are useful for treatment of a wide variety of diseases and disorders, which are cited specifically in claims. Approx. 100 specific examples of I are given, many with synthetic details. For example, 3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]octan-2-one (preparation given) underwent a sequence of: (1) reduction of the amide carbonyl using LiAlH4 (94%); (2) 8-N-acylation with chloroacetyl chloride (69%); and (3) etherification with 2-nitro-4-trifluoromethylphenol (58%), to give title compound II. In a bioassay for the ability to inhibit chemotaxis of various cells (THP-1 cells, primary human monocytes, or primary lymphocytes) in vitro, all example compds. had IC50 values of less than 10 μM.

IT 1100983-96-7 1100983-97-8 1100983-98-9
1100983-99-0 1100984-00-6 1100984-01-7
1100984-02-8 1100984-03-9 1100984-04-0
1100984-05-1 1100984-06-2 1100984-07-3
1100984-08-4 1100984-09-5 1100984-10-8
1100984-11-9 1100984-12-0 1100984-13-1
1100984-15-3 1100984-16-4 1100984-17-5
1100984-18-6 1100984-19-7 1100984-20-0
1100984-21-1 1100984-22-2 1100984-23-3
1100984-24-4 1100984-25-5 1100984-26-6
1100984-27-7 1100984-28-8 1100984-29-9
1100984-30-2 1100984-31-3 1100984-32-4
1100984-33-5 1100984-34-6 1100984-35-7
1100984-36-8 1100984-37-9
RL: PRPH (Prophetic)
(Bridged piperazine derivatives, specifically 3,8-diazabicyclo[3.2.1]octane, 8-azabicyclo[3.2.1]octane, 2,5-diazabicyclo[2.2.2]octane, and 3,9-diazabicyclo[3.3.1]nonane derivatives, useful as inhibitors of chemokines binding to CCR1 receptors, for treating inflammation and other immune disorders.)

RN 1100983-96-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 1100983-97-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100983-98-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100983-99-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-00-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 1100984-01-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-02-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-03-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-04-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-05-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-06-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-07-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-08-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-09-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-10-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-11-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-12-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-13-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-15-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-16-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-17-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-18-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-19-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-20-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-21-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-22-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-23-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-24-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-25-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-26-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-27-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-28-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-29-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-30-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-31-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-32-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100984-33-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-34-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-35-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-36-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1100984-37-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT 417726-56-8P 417726-79-5P,
2-(2-Amino-5-chlorophenoxy)-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]ethanone 417726-95-5P,
2-(4-Chloro-2-nitrophenoxy)-1-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone 417726-96-6P,
4-Chloro-2-[2-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoic acid methyl ester 417726-99-9P
417727-03-8P, N-(2-Aminoethyl)-5-chloro-2-[2-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzamide 417727-08-3P,
2-(2-Amino-4-chlorophenoxy)-1-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone 417727-18-5P,
2-(2-Aminomethyl-4-chlorophenoxy)-1-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of bridged piperazine derivs. as inhibitors of chemokines binding to CCR1 receptors)
RN 417726-56-8 CAPLUS
CN Benzamide, N-(2-aminoethyl)-4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-79-5 CAPLUS
CN Ethanone, 2-(2-amino-5-chlorophenoxy)-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)



RN 417726-95-5 CAPLUS
CN Ethanone, 2-(4-chloro-2-nitrophenoxy)-1-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)



RN 417726-96-6 CAPLUS
CN Benzoic acid, 4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-, methyl ester (CA INDEX NAME)



RN 417726-99-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 417727-03-8 CAPLUS
CN Benzamide, N-(2-aminoethyl)-5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417727-08-3 CAPLUS
CN Ethanone, 2-(2-amino-4-chlorophenoxy)-1-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)



RN 417727-18-5 CAPLUS
CN Ethanone, 2-[2-(aminomethyl)-4-chlorophenoxy]-1-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)



IT 417726-39-7P, 1-[3-(4-Fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-(2-nitro-4-trifluoromethylphenoxy)ethanone 417726-40-0P, 4-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzamide 417726-41-1P, 1-[3-(4-Fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-(2-ethoxycarbonyl-4-chlorophenoxy)ethanone 417726-42-2P, 1-[3-(4-Fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-(2-acetyl-5-chlorophenoxy)ethanone 417726-43-3P, 1-[3-(4-Fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-(2-sulfamoyl-5-chlorophenoxy)ethanone 417726-44-4P, 1-[3-(4-Fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-(2-nitro-5-trifluoromethylphenoxy)ethanone 417726-45-5P, 1-[3-(4-Fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-[2-[(ethoxycarbonyl)methyl]-5-chlorophenoxy]ethanone 417726-46-6P, 5-Chloro-2-[2-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]benzenesulfonamide 417726-47-7P, 4-Chloro-2-[2-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]benzenesulfonamide 417726-48-8P, 4-Chloro-2-[2-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]benzamide 417726-49-9P, 5-Methoxy-2-[2-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]benzamide 417726-50-2P, 4-Chloro-2-[2-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]-1-nitrobenzene 417726-57-9P, 4-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoic acid 417726-58-0P, 4-Methyl-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoic acid 417726-59-1P, 4-Methoxy-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoic acid 417726-60-4P, 4-Iodo-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoic acid 417726-61-5P, 4-Bromo-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoic acid 417726-62-6P, 4-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzeneacetic acid 417726-63-7P, 5-Chloro-2-[2-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]benzoic acid 417726-65-9P, 3-[2-[3-(4-Fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]naphthalene-2-carboxylic acid 417726-66-0P, 4-Chloro-1-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]naphthalene-2-carboxylic acid 417726-67-1P, 5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(1H-tetrazol-5-yl)benzamide 417726-68-2P, 4-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(carboxymethyl)benzamide 417726-69-3P, 4-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(methanesulfonyl)benzamide 417726-70-6P,

4-Chloro-2-[2-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]-N-(1H-tetrazol-5-yl)benzamide 417726-71-7P, 4-Chloro-2-[2-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]-N-(carbamoylmethyl)benzamide 417726-73-9P, 4-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(2-ureidoethyl)benzamide 417726-74-0P, 1-[5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]-3-(carbamoylmethyl)urea 417726-75-1P, N-[4-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]urea 417726-76-2P, 1-[4-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]-3-(2-carboxyethyl)urea 417726-77-3P, [5-Chloro-2-[2-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]phenyl]urea 417726-80-8P, 2-(2-Amino-4-trifluoromethylphenoxy)-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]ethanone 417726-81-9P, 2-(2-Amino-4-chlorophenoxy)-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]ethanone 417726-82-0P, 2-(2-Amino-4-chlorophenoxy)-1-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]ethanone 417726-86-4P, N-[5-Chloro-2-[2-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]phenyl]-3-hydroxy-3-methylbutyramide 417726-87-5P, N-[4-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]methanesulfonamide 417726-88-6P, N-[5-(Trifluoromethyl)-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]methanesulfonamide 417726-89-7P, N-[5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]methanesulfonamide 417726-90-0P, N-[2-[[[4-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]carbonyl]amino]ethyl]methanesulfonamide 417726-91-1P, N-[5-Chloro-2-[2-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]phenyl]methanesulfonamide 417726-94-4P, 2-(4-Chlorophenoxy)-1-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone 417726-97-7P, 2-(4-Chloro-2-acetylphenoxy)-1-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone 417726-98-8P, 5-Chloro-2-[2-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzenesulfonamide 417727-00-5P, 2-(4-Trifluoromethyl-2-nitrophenoxy)-1-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone 417727-01-6P, 2-[5-Methyl-2-(acetylamino)phenoxy]-1-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone 417727-02-7P, 5-Chloro-2-[2-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzamide 417727-04-9P, 5-Chloro-2-[2-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(2-ureidoethyl)benzamide 417727-05-0P, 2-(5-Chloro-2-ureidophenoxy)-1-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone 417727-06-1P, 2-(5-Trifluoromethyl-2-ureidophenoxy)-1-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone 417727-07-2P, 2-(4-Chloro-2-ureidophenoxy)-1-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone 417727-09-4P, 2-(2-Amino-4-trifluoromethylphenoxy)-1-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone 417727-10-7P, 2-(2-Amino-5-chlorophenoxy)-1-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]ethanone 417727-11-8P, N-[5-Chloro-2-[2-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-

oxoethoxy]phenyl]methanesulfonamide 417727-12-9P,
N-[5-Trifluoromethyl-2-[2-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]-
2-oxoethoxy]phenyl]methanesulfonamide 417727-13-0P,
N-[4-Chloro-2-[2-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-
oxoethoxy]phenyl]methanesulfonamide 417727-14-1P,
N-(Methylsulfonyl)-N-[4-chloro-2-[2-[3-(4-fluorobenzyl)-8-
azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]methanesulfonamide
417727-15-2P, N-[2-[[4-Chloro-2-[2-[3-(4-fluorobenzyl)-8-
azabicyclo[3.2.1]oct-8-yl]-2-
oxoethoxy]phenyl]amino]ethyl]methanesulfonamide 417727-16-3P,
N-[2-[[5-Chloro-2-[2-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-
oxoethoxy]phenyl]amino]ethyl]methanesulfonamide 417727-17-4P,
N-[5-Chloro-2-[2-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-
oxoethoxy]phenyl]-2,2,2-trifluoromethanesulfonamide 417727-19-6P
, N-[5-Chloro-2-[2-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-
oxoethoxy]benzyl]-2-ureidoacetamide 417727-22-1P,
2-(4-Chlorophenoxy)-1-[5-(4-fluorobenzyl)-2,5-diazabicyclo[2.2.2]oct-2-
yl]ethanone 417727-23-2P,
5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-2-
oxoethoxy]benzenesulfonamide 417727-24-3P,
5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-2-
oxoethoxy]benzoic acid methyl ester 417727-25-4P,
N-[5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-2-
oxoethoxy]phenyl]methanesulfonamide 417727-26-5P,
4-Chloro-2-[2-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-2-
oxoethoxy]-1-nitrobenzene 417727-27-6P,
5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-2-
oxoethoxy]benzeneacetic acid ethyl ester 417727-28-7P,
5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-2-
oxoethoxy]benzoic acid 417727-29-8P,
[5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-2-
oxoethoxy]phenyl]acetic acid 417727-33-4P,
N-[[5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-2-
oxoethoxy]phenyl]acetyl]methanesulfonamide 417727-34-5P,
5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-2-
oxoethoxy]-N-(1H-tetrazol-5-yl)benzamide 417727-62-9P,
5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,9-diazabicyclo[3.3.1]non-9-yl]-2-
oxoethoxy]benzamide 417727-75-4P,
5-Chloro-2-[2-[3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-
oxoethoxy]benzoic acid methyl ester 417728-09-7P,
5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-
oxoethoxy]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of bridged piperazine derivs. as inhibitors of
chemokines binding to CCR1 receptors)

RN 417726-39-7 CAPLUS

CN Ethanone, 1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-
[2-nitro-4-(trifluoromethyl)phenoxy]- (CA INDEX NAME)



RN 417726-40-0 CAPLUS
CN Benzamide, 4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-41-1 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-, ethyl ester (CA INDEX NAME)



RN 417726-42-2 CAPLUS
CN Ethanone, 2-(2-acetyl-5-chlorophenoxy)-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)



RN 417726-43-3 CAPLUS

CN Benzenesulfonamide, 4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-44-4 CAPLUS
CN Ethanone, 1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-[2-nitro-5-(trifluoromethyl)phenoxy]- (CA INDEX NAME)



RN 417726-45-5 CAPLUS
CN Benzeneacetic acid, 4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-, ethyl ester (CA INDEX NAME)



RN 417726-46-6 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[2-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-47-7 CAPLUS
CN Benzenesulfonamide, 4-chloro-2-[2-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-48-8 CAPLUS
CN Benzamide, 4-chloro-2-[2-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-49-9 CAPLUS
CN Benzamide, 2-[2-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]-5-methoxy- (CA INDEX NAME)



RN 417726-50-2 CAPLUS
CN Ethanone, 2-(5-chloro-2-nitrophenoxy)-1-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]- (CA INDEX NAME)



RN 417726-57-9 CAPLUS
CN Benzoic acid, 4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-58-0 CAPLUS
CN Benzoic acid, 2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-4-methyl- (CA INDEX NAME)



RN 417726-59-1 CAPLUS
CN Benzoic acid, 2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-4-methoxy- (CA INDEX NAME)



RN 417726-60-4 CAPLUS
CN Benzoic acid, 2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-4-iodo- (CA INDEX NAME)



RN 417726-61-5 CAPLUS
CN Benzoic acid, 4-bromo-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-62-6 CAPLUS
CN Benzeneacetic acid, 4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-63-7 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-65-9 CAPLUS
CN 2-Naphthalenecarboxylic acid, 3-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-66-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-chloro-1-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-67-1 CAPLUS
CN Benzamide, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-2H-tetrazol-5-yl- (CA INDEX NAME)



RN 417726-68-2 CAPLUS
CN Glycine, N-[4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoyl]- (CA INDEX NAME)



RN 417726-69-3 CAPLUS
CN Benzamide, 4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)



RN 417726-70-6 CAPLUS
CN Benzamide, 4-chloro-2-[2-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]-N-2H-tetrazol-5-yl- (CA INDEX NAME)



RN 417726-71-7 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-4-chloro-2-[2-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-73-9 CAPLUS
CN Benzamide, N-[2-[(aminocarbonyl)amino]ethyl]-4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417726-74-0 CAPLUS
CN Acetamide, 2-[[[[5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]amino]carbonyl]amino]- (CA INDEX NAME)



RN 417726-75-1 CAPLUS
CN Urea, N-[4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 417726-76-2 CAPLUS
CN β-Alanine, N-[[[4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 417726-77-3 CAPLUS
CN Urea, N-[5-chloro-2-[2-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 417726-80-8 CAPLUS
CN Ethanone, 2-[2-amino-4-(trifluoromethyl)phenoxy]-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)



RN 417726-81-9 CAPLUS
CN Ethanone, 2-(2-amino-4-chlorophenoxy)-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)



RN 417726-82-0 CAPLUS
CN Ethanone, 2-(2-amino-4-chlorophenoxy)-1-[8-[(4-fluorophenyl)methyl]-3,8-

diazabicyclo[3.2.1]oct-3-yl]- (CA INDEX NAME)



RN 417726-86-4 CAPLUS
CN Butanamide, N-[5-chloro-2-[2-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]phenyl]-3-hydroxy-3-methyl- (CA INDEX NAME)



RN 417726-87-5 CAPLUS
CN Methanesulfonamide, N-[4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 417726-88-6 CAPLUS
CN Methanesulfonamide, N-[2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 417726-89-7 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 417726-90-0 CAPLUS
CN Benzamide, 4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-[2-[(methylsulfonyl)amino]ethyl]- (CA INDEX NAME)



RN 417726-91-1 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[2-[8-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-3-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 417726-94-4 CAPLUS
CN Ethanone, 2-(4-chlorophenoxy)-1-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)



RN 417726-97-7 CAPLUS
CN Ethanone, 2-(2-acetyl-4-chlorophenoxy)-1-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)



RN 417726-98-8 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417727-00-5 CAPLUS
CN Ethanone, 1-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-[2-nitro-4-(trifluoromethyl)phenoxy]- (CA INDEX NAME)



RN 417727-01-6 CAPLUS
CN Acetamide, N-[2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-4-methylphenyl]- (CA INDEX NAME)



RN 417727-02-7 CAPLUS
CN Benzamide, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417727-04-9 CAPLUS
CN Benzamide, N-[2-[(aminocarbonyl)amino]ethyl]-5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417727-05-0 CAPLUS
CN Urea, N-[4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 417727-06-1 CAPLUS
CN Urea, N-[2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 417727-07-2 CAPLUS
CN Urea, N-[5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 417727-09-4 CAPLUS
CN Ethanone, 2-[2-amino-4-(trifluoromethyl)phenoxy]-1-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)



RN 417727-10-7 CAPLUS
CN Ethanone, 2-(2-amino-5-chlorophenoxy)-1-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)



RN 417727-11-8 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 417727-12-9 CAPLUS
CN Methanesulfonamide, N-[2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 417727-13-0 CAPLUS
CN Methanesulfonamide, N-[4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-

azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)



RN 417727-14-1 CAPLUS
CN Methanesulfonamide, N-[4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]-N-(methylsulfonyl)- (CA INDEX NAME)



RN 417727-15-2 CAPLUS
CN Methanesulfonamide, N-[2-[[4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]amino]ethyl]- (CA INDEX NAME)



RN 417727-16-3 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]amino]ethyl]- (CA INDEX NAME)



RN 417727-17-4 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]-1,1,1-trifluoro- (CA INDEX NAME)



RN 417727-19-6 CAPLUS
CN Acetamide, 2-[(aminocarbonyl)amino]-N-[[5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 417727-22-1 CAPLUS
CN Ethanone, 2-(4-chlorophenoxy)-1-[5-[(4-fluorophenyl)methyl]-2,5-diazabicyclo[2.2.2]oct-2-yl]- (CA INDEX NAME)



RN 417727-23-2 CAPLUS
CN Benzenesulfonamide, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417727-24-3 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]-, methyl ester (CA INDEX NAME)



RN 417727-25-4 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]phenyl]- (CA INDEX NAME)





RN 417727-26-5 CAPLUS
CN Ethanone, 2-(5-chloro-2-nitrophenoxy)-1-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]- (CA INDEX NAME)



RN 417727-27-6 CAPLUS
CN Benzeneacetic acid, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]-, ethyl ester (CA INDEX NAME)



RN 417727-28-7 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417727-29-8 CAPLUS
CN Benzeneacetic acid, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417727-33-4 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)



RN 417727-34-5 CAPLUS
CN Benzamide, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]-N-2H-tetrazol-5-yl- (CA INDEX NAME)



RN 417727-62-9 CAPLUS
CN Benzamide, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417727-75-4 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-, methyl ester (CA INDEX NAME)



RN 417728-09-7 CAPLUS
CN Benzamide, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



IT 417727-48-1, 4-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoic acid methyl ester
417727-49-2, 5-Chloro-2-[2-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzoic acid
417727-50-5, 2-(5-Chloro-2-nitrophenoxy)-1-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]ethanone
RL: RCT (Reactant); RACT (Reactant or reagent)
(precursor; preparation of bridged piperazine derivs. as inhibitors of chemokines binding to CCR1 receptors)

RN 417727-48-1 CAPLUS
CN Benzoic acid, 4-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-, methyl ester (CA INDEX NAME)



RN 417727-49-2 CAPLUS
CN Benzoic acid, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]- (CA INDEX NAME)



RN 417727-50-5 CAPLUS
CN Ethanone, 2-(5-chloro-2-nitrophenoxy)-1-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:222006 CAPLUS
DOCUMENT NUMBER: 134:252354
TITLE: Preparation of N-benzylpiperazines as antiinflammatory agents
INVENTOR(S): Bauman, John G.; Buckman, Brad O.; Ghannam, Ameen F.; Hesselgesser, Joseph E.; Horuk, Richard; Islam, Imadul; Liang, Meina; May, Karen B.; Monahan, Sean D.; Morrissey, Michael M.; Ng, Howard P.; Wei, Guo Ping; Xu, Wei; Zheng, Wei
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: U.S., 87 pp., Cont.-in-part of U.S. Ser. No. 873,599, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6207665	B1	20010327	US 1998-94397	19980609
CA 2293382	A1	19981217	CA 1998-2293382	19980611
CA 2293382	C	20080311		
AU 9886258	A	19981230	AU 1998-86258	19980611
AU 735462	B2	20010712		
EP 988292	A2	20000329	EP 1998-937467	19980611
EP 988292	B1	20030212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EE 9900565	A	20000615	EE 1999-565	19980611
EE 4056	B1	20030616		
TR 9903034	T2	20000621	TR 1999-3034	19980611
HU 2000003929	A2	20010528	HU 2000-3929	19980611
HU 2000003929	A3	20010828		
JP 2002503239	T	20020129	JP 1999-501611	19980611
EP 1254899	A2	20021106	EP 2002-90193	19980611
EP 1254899	A3	20030219		
EP 1254899	B1	20050525		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 232522	T	20030215	AT 1998-937467	19980611
EE 200200682	A	20030415	EE 2002-682	19980611
EE 200200683	A	20030415	EE 2002-683	19980611
EE 200200684	A	20030415	EE 2002-684	19980611
ES 2191320	T3	20030901	ES 1998-937467	19980611
IL 132398	A	20040831	IL 1998-132398	19980611
AT 296292	T	20050615	AT 2002-90193	19980611
PT 1254899	E	20051031	PT 2002-90193	19980611
CZ 295784	B6	20051116	CZ 1999-4481	19980611
ES 2242824	T3	20051116	ES 2002-90193	19980611
SK 285162	B6	20060707	SK 1999-1713	19980611
SK 285445	B6	20070104	SK 2005-79	19980611
NO 9906068	A	20000211	NO 1999-6068	19991209
NO 317343	B1	20041011		
MX 9911506	A	20000430	MX 1999-11506	19991210
US 6541476	B1	20030401	US 2000-713606	20001114

US 6534509	B1	20030318	US 2000-713881	20001115
US 6573266	B1	20030603	US 2000-714937	20001116
US 20020177598	A1	20021128	US 2000-726808	20001129
US 6555537	B2	20030429		
US 20030139425	A1	20030724	US 2003-347530	20030117
US 6977258	B2	20051220		
US 20030158205	A1	20030821	US 2003-347529	20030117
US 6972290	B2	20051206		
NO 2003001373	A	20000211	NO 2003-1373	20030326
US 20060135487	A1	20060622	US 2005-248618	20051013
US 7268140	B2	20070911		

PRIORITY APPLN. INFO.:

US 1997-873599	B2 19970612
US 1998-94397	A 19980609
EP 1998-937467	A3 19980611
WO 1998-EP3503	W 19980611
US 2000-714937	A3 20001116
US 2000-726808	A1 20001129
US 2003-347530	A3 20030117

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 134:252354

GI



I



II

AB Title compds. [I; R = R3Z3Z2Z1; R1 = ≥1 of halo, alkyl, aryl, etc.; R2 = (un)substituted Ph; R3 = (un)substituted carbocyclic ring system (sic) or (un)substituted heterocyclic ring system (sic); Z1 = bond, CH2, CO, etc.; Z2 = alkylene or alkylidene; Z3 = bond, O, CH2, (alkyl)imino, etc.] were prepared as chemokine inhibitors (no data). Thus, (2R,5S)-1-(4-fluorobenzyl)-2-hydroxymethyl-5-methylpiperazine was N-acylated by 4-ClC6H4OCH2COCl to give title compound (R,R)-II.

IT 217644-61-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-benzylpiperazines as antiinflammatory agents)

RN 217644-61-6 CAPLUS

CN Ethanone, 2-(4-chlorophenoxy)-1-[7-[(4-fluorophenyl)methyl]-4,7-diazaspiro[2.5]oct-4-yl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT:	12	THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)
REFERENCE COUNT:	49	THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:163659 CAPLUS
DOCUMENT NUMBER: 130:311766
TITLE: Solid-Phase Synthesis of Substituted 4-Acyl-1,2,3,4-tetrahydroquinoxalin-2-ones
AUTHOR(S): Zaragoza, Florencio; Stephensen, Henrik
CORPORATE SOURCE: Novo Nordisk A/S, Maalov, DK-2760, Den.
SOURCE: Journal of Organic Chemistry (1999), 64(7), 2555-2557
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 130:311766
GI



AB Resin-bound bis(chloroacetamido)benzoates, e.g. I (R = Wang resin), are prepared to serve as intermediates for the solid phase synthesis of 1,2,3,4-tetrahydroquinoxalin-2-ones, e.g. II. This method allowed for preparation of tetrahydroquinoxalin-2-ones with sufficient purity to be directly used in biol. assays.
IT 223678-89-5P 223678-94-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid phase synthesis of substituted tetrahydroquinoxalinones via nucleophilic ring closure of resin bound bis(chloroacetamido)benzoates)
RN 223678-89-5 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 1-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydro-4-[3-(2-naphthalenyl)-1-oxo-2-propen-1-yl]-2-oxo- (CA INDEX NAME)



RN 223678-94-2 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 1-[(4-chlorophenyl)methyl]-4-[3-(4-chlorophenyl)-1-oxo-2-propen-1-yl]-1,2,3,4-tetrahydro-2-oxo- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT:	36	THERE ARE 36 CAPLUS RECORDS THAT CITE THIS RECORD (36 CITINGS)
REFERENCE COUNT:	20	THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:7977 CAPLUS
DOCUMENT NUMBER: 130:66509
TITLE: Preparation of N-benzylpiperazines as antiinflammatory agents
INVENTOR(S): Bauman, John G.; Buckman, Brad O.; Ghannam, Ameen F.; Hesselgesser, Joseph E.; Horuk, Richard; Islam, Imadul; Liang, Meina; May, Karen B.; Monahan, Sean D.; Morissey, Michael M.; Ng, Howard P.; Wei, Guo Ping; Xu, Wei; Zheng, Wei
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 309 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856771	A2	19981217	WO 1998-EP3503	19980611
WO 9856771	A3	19990311		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2293382	A1	19981217	CA 1998-2293382	19980611
CA 2293382	C	20080311		
AU 9886258	A	19981230	AU 1998-86258	19980611
AU 735462	B2	20010712		
EP 988292	A2	20000329	EP 1998-937467	19980611
EP 988292	B1	20030212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EE 9900565	A	20000615	EE 1999-565	19980611
EE 4056	B1	20030616		
HU 2000003929	A2	20010528	HU 2000-3929	19980611
HU 2000003929	A3	20010828		
JP 2002503239	T	20020129	JP 1999-501611	19980611
AT 232522	T	20030215	AT 1998-937467	19980611
EE 200200682	A	20030415	EE 2002-682	19980611
EE 200200683	A	20030415	EE 2002-683	19980611
EE 200200684	A	20030415	EE 2002-684	19980611
IL 132398	A	20040831	IL 1998-132398	19980611
SK 285162	B6	20060707	SK 1999-1713	19980611
SK 285445	B6	20070104	SK 2005-79	19980611
NO 9906068	A	20000211	NO 1999-6068	19991209
NO 317343	B1	20041011		
MX 9911506	A	20000430	MX 1999-11506	19991210
NO 2003001373	A	20000211	NO 2003-1373	20030326

PRIORITY APPLN. INFO.:		
US 1997-873599	A	19970612
US 1998-94397	A	19980609
WO 1998-EP3503	W	19980611

OTHER SOURCE(S): MARPAT 130:66509
GI



AB Title compds. [I; R = R3Z3Z2Z1; R1 = ≥1 of halo, alkyl, aryl, etc.; R2 = (un)substituted Ph; R3 = (un)substituted carbocyclic ring system (sic) or (un)substituted heterocyclic ring system (sic); Z1 = bond, CH2, CO, etc.; Z2 = alkylene or alkylidene; Z3 = bind, O, CH2, (alkyl)imino, etc.] were prepared as chemokine inhibitors (no data). Thus, (2R,5S)-1-(4-fluorobenzyl)-2-hydroxymethyl-5-methylpiperazine was N-acylated by 4-ClC6H4OCH2COCl to give title compound (R,R)-II.

IT 217644-61-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-benzylpiperazines as antiinflammatory agents)

RN 217644-61-6 CAPLUS

CN Ethanone, 2-(4-chlorophenoxy)-1-[7-[(4-fluorophenyl)methyl]-4,7-diazaspiro[2.5]oct-4-yl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT:	23	THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
REFERENCE COUNT:	13	THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1972:85788 CAPLUS
DOCUMENT NUMBER: 76:85788
ORIGINAL REFERENCE NO.: 76:13799a,13802a
TITLE: Bicyclic homologs of piperazine. XI. 3,8-Diazabicyclo[3.2.1]octane-2,4-diones with potential pharmacological activity
AUTHOR(S): Fontanella, L.; Occelli, E.
CORPORATE SOURCE: Lab. Ric., Gruppo Lepetit S.p.A., Milan, Italy
SOURCE: Farmaco, Edizione Scientifica (1972), 27(1), 68-78
CODEN: FRPSAX; ISSN: 0430-0920
DOCUMENT TYPE: Journal
LANGUAGE: Italian
GI For diagram(s), see printed CA Issue.
AB The 3-substituted 3,8-diazabicyclo[3.2.1]octane-2,4-diones, I (R = H), are alkylated and acylated and treated with isocyanates to give 3,8-disubstituted compds. I (R = H, R1 = Me) is treated with BuI to give I (R = Bu, R1 = Me). Similarly prepared are .apprx.30 addnl. I (R = alkyl, acyl, CONH2, CONHPh; R1 = H, Me, PhCH2, aryl). II is treated with NH3 to give I (R = Me, R1 = H); and I (R = H, R1 = p-tolyl) is prepared by the distillation of III.
IT 35101-52-1
RL: PROC (Process)
(preparation of)
RN 35101-52-1 CAPLUS
CN 3,8-Diazabicyclo[3.2.1]octane-2,4-dione, 8-(1-oxo-2-phenyl-2-propenyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 12 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN
RN 868524-42-9 REGISTRY
ED Entered STN: 21 Nov 2005
CN Urea, N-[5-chloro-2-[(1E)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]non-9-yl]-3-oxo-1-propen-1-yl]phenyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3,7,9-Triazabicyclo[3.3.1]nonane, 9-[(2E)-3-[2-[(aminocarbonyl)amino]-4-chlorophenyl]-1-oxo-2-propenyl]-3-[(4-fluorophenyl)methyl]- (9CI)
FS STEREOSEARCH
MF C23 H25 Cl F N5 O2
CI COM
SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT